

Date of this document:  
April 2020. Updated in

line with proposed  
Annex A of National  
tariff payment system  
2020/21 issued 19.12.19  
and cross-referenced  
with NHSE V15  
spreadsheet issued  
April 2020  
This version approved  
at HCDSG 24/6/20

<b>Commissioner category:</b> C= CCG N= NHS England N*= expected to be NHSE but not on V15 s/sheet	<b>Further notes available at foot of spreadsheet</b> N.B. for NHSE-commissioned drugs, consult NHSE information for commissioning policy / position.	<b>Note:</b> many BNF Categories inserted using NDO on NHSE s/sheet where Annex C of NHSE s/sheet says "none" or "n/a"	<b>Group:</b> A group includes all drugs in that group regardless of specific drugs listed. Individual - This is for the specific listed drug only	Drugs in blue cells are new additions for 2020/21. Probable commissioner indicated	Highlighted cells are amendments made to 2019/20 version	Highlighted cells updated in-year		
---	--	--	--	--	--	-----------------------------------	--	--

**Date of approval at High Cost Drugs Group: 24th June 2020**

No.	Drug Name <i>(some brand names added for clarity in italics)</i>	Commissioner Category	PBR Category	BNF category (legacy)	Group	Indication	Prior Approval Category	Commissioning Policy Type	Commissioning Policy Link	Comments
1	Abacavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
2	Abacavir with dolutegravir and lamivudine <i>Triumeq</i>	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				included to match NHSE list
3	Abacavir with lamivudine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				included to match NHSE list
4	Abaloparatide	N	Drugs affecting bone metabolism	6.6.2	Individual	Male and juvenile osteoporosis				s/c injection.
5	Abaloparatide	C	Drugs affecting bone metabolism	6.6.2	Individual	Postmenopausal osteoporosis	Not routinely commissioned			s/c injection. new drug, not recommended for approval.
6	Abaloparatide	C	Drugs affecting bone metabolism	6.6.3	Individual	Postmenopausal osteoporosis	Not routinely commissioned			Transdermal patch under development
7	Abatacept	N	Cytokine modulators	10.1.3	Group	Juvenile Idiopathic Rheumatoid Arthritis			<a href="http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf">http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf</a>	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
8	Abatacept	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)		As per adult TAs (TA195, TA280)		
9	Abatacept	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of conventional DMARDs	Monitored	NICE TA375 / GM Harmonised biologics pathway	<a href="http://www.nice.org.uk/guidance/ta375">http://www.nice.org.uk/guidance/ta375</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf</a>	
10	Abatacept	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, if rituximab contra-indicated	Monitored	NICE TA195	<a href="http://guidance.nice.org.uk/TA195">http://guidance.nice.org.uk/TA195</a>	
11	Abatacept	C	Cytokine modulators	10.1.3	Group	psoriatic arthritis after DMARDs	Not routinely commissioned	NICE TA568	<a href="https://www.nice.org.uk/guidance/ta568">https://www.nice.org.uk/guidance/ta568</a>	NICE TAG terminated - unable to recommend use
12	Abicipar (pegol)	C	Subfoveal choroidal neovascularisation		Group	Neovascular age-related macular degeneration (AMD)	Not routinely commissioned			NICE TA in development but paused 04/20
13	Abiraterone	N	Hormone antagonists	8.3.4.2		Cancer				included to match NHSE list
14	Actoxumab	C	Antibacterial Drugs	5.1.7	Group	for prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence	Not routinely commissioned			re-inserted to accord with national list
15	Adalimumab	N	Cytokine modulators	10.1.3	Group	Hidradenitis Suppurativa				

										For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
16	Adalimumab	N	Cytokine modulators	10.1.3	Group	Juvenile Arthritis				
17	Adalimumab	N	Cytokine modulators	10.1.3	Group	Uveitis [paediatric]				
18	Adalimumab	N	Cytokine modulators	10.1.3	Group	Uveitis [adult]				
19	Adalimumab	C	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	NICE TA383 / GM Harmonised Pathway for biologics in AS and PsA.	<a href="http://guidance.nice.org.uk/TA383">http://guidance.nice.org.uk/TA383</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	
20	Adalimumab	C	Cytokine modulators	13.5.3	Group	Psoriasis (plaque)	Monitored	NICE TA146	<a href="http://guidance.nice.org.uk/TA146">http://guidance.nice.org.uk/TA146</a>	
21	Adalimumab	C	Cytokine modulators	10.1.3	Group	Psoriatic Arthritis	Monitored	NICE TA199 / GM Harmonised Pathway for biologics in AS and PsA.	<a href="http://guidance.nice.org.uk/TA199">http://guidance.nice.org.uk/TA199</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	
22	Adalimumab	N	Cytokine modulators	13.5.3	Group	Plaque psoriasis in children			added to accord with NHSE V15	
23	Adalimumab	C	Cytokine modulators	13.5.3	Group	Psoriasis (plaque) - sequential use of biologic agents	Monitored	GMMMG	<a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>	
24	Adalimumab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of conventional DMARDs	Monitored	NICE TA375 / GM Harmonised biologics pathway	<a href="http://www.nice.org.uk/guidance/ta375">http://www.nice.org.uk/guidance/ta375</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf</a>	
25	Adalimumab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, if rituximab contra-indicated, or as monotherapy if rituximab and methotrexate contra-indicated	Monitored	NICE TA195 / GM Harmonised biologics pathway	<a href="http://guidance.nice.org.uk/TA195">http://guidance.nice.org.uk/TA195</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf</a>	
26	Adalimumab	C	Cytokine modulators	1.5.3	Group	Crohn's Disease, gastroenterology	Monitored	NICE TA187	<a href="http://guidance.nice.org.uk/TA187">http://guidance.nice.org.uk/TA187</a>	
27	Adalimumab	C	Cytokine modulators	1.5.3	Group	Ulcerative colitis, gastroenterology	Monitored	NICE TA329	<a href="http://www.nice.org.uk/guidance/ta329">http://www.nice.org.uk/guidance/ta329</a>	
28	Adalimumab	C	Cytokine modulators	10.1.3	Group	All other adult indications	Not routinely commissioned			
29	Adalimumab	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)		TA 455 or as per adult TA's (TA103, TA375, TA143, TA199)		Funding for paediatric indications not being treated at an NHSE-commissioned Specialist Centre may also fall to CCGs
30	Adalimumab	N	Cytokine modulators	10.1.3	Group	Behçet's Syndrome				Added to match NHSE s/sheet
31	Adefovir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis B				

32	Afamelanotide	C?	Skin Conditions	13.1	Individual	Erythropoietic protoporphyria (EPP)	Not routinely commissioned			SPS suggests commissioner is NHSE but that would be for treatment of severe disease and this is licensed for prevention. Commissioner to be clarified. NICE Final Evaluation Determination (Highly Specialised Technologies) is negative. Not in NHSE V15
33	Afatinib	N	Protein kinase inhibitors	8.1.5	Individual					
34	Aflibercept	N	Cancer exclusion	8.1		Cancer				Added to match NHSE s/sheet
35	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Neovascular (wet) age-related macular degeneration (AMD)	Monitored	NICE TA294	<a href="http://guidance.nice.org.uk/TA294">http://guidance.nice.org.uk/TA294</a>	
36	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Visual impairment caused by macular oedema secondary to central retinal vein occlusion	Monitored	NICE TA305	<a href="http://www.nice.org.uk/guidance/TA305">http://www.nice.org.uk/guidance/TA305</a>	
37	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Visual impairment caused by macular oedema secondary to branch retinal vein occlusion	Monitored	NICE TA 409	<a href="https://www.nice.org.uk/guidance/ta409">https://www.nice.org.uk/guidance/ta409</a>	
38	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Diabetic macular oedema	Monitored	NICE TA346	<a href="http://www.nice.org.uk/guidance/ta346">http://www.nice.org.uk/guidance/ta346</a>	
39	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.3	Individual	Myopic choroidal neovascularisation	Monitored	NICE TA486	<a href="https://www.nice.org.uk/guidance/ta486">https://www.nice.org.uk/guidance/ta486</a>	
40	Agalsidase alfa	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Fabry's disease				
41	Agalsidase beta	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Fabry's disease				
42	Aganirsen	N*	Subfoveal choroidal neovascularisation	11.8.2	Individual	Corneal neovascularisation associated with keratoplasty rejection				NHSE commissions keratoplasty [PSS No.12] Not in SPS
43	Alafenamide	N	AIDS/HIV antiretrovirals		Group	HIV				Tenofovir alafenamide is a pro-drug of tenofovir with the aim of improving renal and bone safety should really be with tenofovir which is where NHSE lists it.
44	Albutropin	N	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Individual	Growth hormone deficiency adult onset				An albumin/somatropin fusion protein that acts as a growth hormone receptor agonist.
45	Aldesleukin	N	Immunomodulating drugs	8.2.4	Individual	cancer				
46	Alemtuzumab	N	Drugs affecting the immune response	8.2.3	Individual	Multiple Sclerosis				
47	Alemtuzumab	N	Drugs affecting the immune response	8.2.3	Individual	Pre-transplant immunosuppression				
48	Alemtuzumab	N	Drugs affecting the immune response	8.2.3	Individual	CLL				
49	Alemtuzumab	N	Drugs affecting the immune response	8.2.3	Individual	Behçet's Syndrome				Added to match NHSE s/sheet
50	Alglucosidase alfa (Lumizyme® Myozyme®)	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Pompe disease - late onset (pts 8yrs & over)				

51	Alicaforsen	C		1.5	Individual	Pouchitis	Not routinely commissioned			
52	Alipogene Tiparovec	N	Drugs used in Metabolic disorders	9.8	Individual	Hyperlipoproteinaemia				Only excluded when used for a metabolic disorder.
53	Alirocumab	C	Lipid regulating drugs	2.12	Individual	Hypercholesterolaemia	Monitored	NICE TA393	<a href="https://www.nice.org.uk/guidance/ta393">https://www.nice.org.uk/guidance/ta393</a>	
54	Alisporivir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	none	Group	Hepatitis C				
55	Alitretinoin	C	Skin Conditions	13.5.1	Individual	Severe chronic hand eczema in adults	Monitored	NICE TA177	<a href="http://guidance.nice.org.uk/TA177">http://guidance.nice.org.uk/TA177</a>	
56	Alpha-1 Antitrypsin	C	Drugs used in Metabolic disorders	3	Individual	Alpha-1 anti-trypsin deficiency: Emphysema	Not routinely commissioned			Inhaled
57	Alpha-1 Antitrypsin	N	Drugs used in Metabolic disorders	6.1	Individual	Graft versus host disease (GvHD)				possible use changed
58	Alpha-Mannosidase recombinant human	N	Lysosomal Storage Disorder drugs	none	Group					
59	Alteplase	C				Acute ischaemic stroke	Monitored	NICE TA264	<a href="http://guidance.nice.org.uk/TA264">http://guidance.nice.org.uk/TA264</a>	Removed from national list. However, a locally agreed tariff for hyper acute stroke units has agreed that this can be re-charged to commissioners.
60	Ambrisentan	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary hypertension				
61	Amifampridine phosphate	N	Neuromuscular Disorders	10.2.1	Individual	Lambert-Eaton Myasthenic Syndrome or Congenital Myasthenia Gravis				
62	Amikacin Inhalation	C	Antibacterial Drugs	5.1.4	Individual	Nontuberculous mycobacterial (NTM) lung infection	Not routinely commissioned			Indication changed. Only when delivered via nebulisation/inhalation
63	Amikacin Inhalation	N	Antibacterial Drugs	5.1.4	Individual	Cystic fibrosis				Only when delivered via nebulisation/inhalation
64	Amikacin liposomal	N	Antibacterial Drugs		Individual	Management of cystic fibrosis				Only when delivered via nebulisation/inhalation
65	Amiselimod	N	Immunomodulating drugs	8.2.4	Group	Likely to be used in multiple sclerosis				Not in SPS nor V15
66	Amphotericin liposomal	N	Antifungals	5.2.3	Individual	Licensed indications and/or Consultant Microbiologist approval only				
67	Anabasum	N	Drugs affecting the immune response	3.11	Individual	Likely to be used in cystic fibrosis or interstitial lung disease				not in SPS. On NHSE V15
68	Anakinra	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, rheumatology [adults]	Not routinely commissioned	NICE CG79	<a href="http://www.nice.org.uk/guidance/CG79">http://www.nice.org.uk/guidance/CG79</a>	Not recommended by NICE for RA; former TA72 now incorporated into updated CG79
69	Anakinra	N	Cytokine modulators	10.1.3	Group	Juvenile Arthritis				
70	Anakinra	N	Cytokine modulators	10.1.3	Group	Paediatric indications				
71	Anakinra	N	Cytokine modulators	10.1.3	Group	Specialist Autoinflammatory disease				
72	Anakinra	N	Cytokine modulators	10.1.3	Group	Cryopyrin Associated Periodic Syndrome / periodic fevers and autoinflammatory conditions				
73	Anakinra	N	Cytokine modulators	10.1.3	Group	Adult onset Still's disease				

74	Andexanet alfa	C	Oral anticoagulant reversal agents	2.8.4	Group	Anticoagulation reversal - antidote to oral factor Xa inhibitors	Not routinely commissioned			GMMMG guidance and NICE TA in progress
75	Anidulafungin	N	Antifungals	5.2.4	Individual	Invasive candidiasis				
76	Anifrolumab	N	Cytokine modulators	8.1	Group	Systemic lupus erythematosus				
77	Antilymphocyte globulin	N	Drugs used in hypoplastic, haemolytic and renal anaemias	9.1.3	Group	Licensed indications				
78	Anti-pseudomonas aeruginosa IgY	N	Antibacterial Drugs	5.1.7	Individual	Pseudomonas Aeruginosa Vaccine				Pseudomonas aeruginosa in ventilated ICU patients - to prevent infections in Cystic Fibrosis patients.
79	Antithrombin III	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
80	Antithymocyte Immunoglobulin	N	Drugs used in hypoplastic, haemolytic and renal anaemias	8.2.2	Group	Licensed indications				
81	Apremilast	C	Cytokine modulators	none	Group	Psoriasis	Monitored	NICE TA419	<a href="https://www.nice.org.uk/guidance/ta419">https://www.nice.org.uk/guidance/ta419</a>	
82	Apremilast	C	Cytokine modulators	none	Group	Psoriatic arthritis	monitored	NICE TA433	<a href="https://www.nice.org.uk/guidance/ta433">https://www.nice.org.uk/guidance/ta433</a>	
83	Apremilast	N	Cytokine modulators	none	Group	Paediatric indications				
84	Arimocloamol	N	Neuromuscular Disorders	4.9.3	Individual	Niemann-Pick disease, type C (NPC) or / and Amyotrophic lateral sclerosis				
85	Asfotase alfa	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Hypophosphatasia				
86	Asunaprevir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
87	Atacicept	N	Drugs affecting the immune response	8.2.2	Individual	Systemic lupus erythematosus (SLE)				
88	Ataluren	N	Neuromuscular Disorders	10.2	Individual	Duchenne Muscular Dystrophy				
89	Atazanavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
90	Atazanavir and Cobicistat	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				Added to match NHSE s/sheet
91	Autologous eye serum drops	N	Blood-related products			Severe dry eyes				ATMP?
92	Avacincaptad pegol	C	Subfoveal choroidal neovascularisation	11.8.2	Group	Age-related macular degeneration (AMD); geographic atrophy (advanced <b>dry</b> -type AMD).	Not routinely commissioned			not before 2023
93	Avacopan	N	Cytokine modulator	10	Group	Anti-neutrophil cytoplasmic antibody-associated vasculitis				
94	Avatrombopag	C	Platelet Disorder Drugs	9.1.4	Individual	Severe thrombocytopenia in adults with chronic liver disease who are scheduled to undergo an invasive procedure	Not routinely commissioned			NICE FAD is positive. Category will change to monitored when a positive TA is issued

95	Axitinib	N	Protein kinase inhibitors	8.1.5	Individual					
96	Azacitidine	N	Myelodysplastic Syndrome	8.1.3	Individual					
97	Aztreonam Lysine [≠nebulised]	N	Antibacterial Drugs	5.1.2.3	Individual	Management of cystic fibrosis				Only when delivered via nebulisation/inhalation
98	Bardoxolone methyl	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.?		Pulmonary Arterial Hypertension				Only when used for Pulmonary Arterial Hypertension
99	Baricitinib	C	Immunomodulating drugs	10.1.3	Individual	Rheumatoid arthritis - selective JAK1 and JAK2 inhibitor	Monitored	NICE TA466	<a href="https://www.nice.org.uk/guidance/ta466">https://www.nice.org.uk/guidance/ta466</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf</a>	
100	Basiliximab	N	Corticosteroids and other immunosuppressants	8.2.2	Individual	Prophylaxis of acute organ rejection - Adolescents and children				
101	Beclabuvir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				Annex A has inserted this as a separate entry but only combination products in NDO.
102	Bedaquiline	N	Antituberculosis drugs	5.1.9	Individual	Extensively drug resistant TB				Two rows to match NHSE s/sheet
103	Bedaquiline	N	Antituberculosis drugs	5.1.9	Individual	Multi drug resistant				Two rows to match NHSE s/sheet
104	Begelomab	N	Malignant disease and immunosuppression	8	Individual	Graft versus host disease (GvHD)				
105	Belatacept	N	Drugs affecting the immune response	8.2.2	Individual	Prevention of organ rejection following renal transplant				
106	Belimumab	N	Drugs affecting the immune response		Individual	Systemic lupus erythematosus (SLE)				
107	Benralizumab	N	Allergen Immunotherapy	3.4	Group	Asthma - uncontrolled on high-dose inhaled corticosteroid + LABA - in adults and adolescents				
108	Benralizumab	C	Allergen Immunotherapy	3.4	Group	COPD	Not routinely commissioned			Monoclonal antibody binding to the interleukin-5 receptor that depletes eosinophils.
109	Benralizumab	C	Allergen Immunotherapy		Group	nasal polyposis	Not routinely commissioned			This indication may precede COPD indication
110	Bepermiogene perplasmid	N		2	Individual	Peripheral vascular disease; arterial disorder				Hepatocyte growth factor gene therapy; naked plasmid DNA (not using a virus vector) Gene therapy.
111	Betaine	N	Drugs used in Metabolic disorders	9.8.1	Individual	Homocystinuria, tetrahydrofolate reductase deficiency, cobalamin cofactor metabolism.				Only excluded when used for a metabolic disorder.
112	Bevacizumab	C	Antineoplastic drugs	11.8.2	Individual	AMD	Not routinely commissioned	GMMMG	<a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG%20recommendation%20Bevacizumab%20wAMD%20Nov%2015.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG%20recommendation%20Bevacizumab%20wAMD%20Nov%2015.pdf</a>	
113	Bevacizumab	N	Antineoplastic drugs	8.1.5	Individual	Cancer				
114	Bevacizumab	N	Antineoplastic drugs	8.1.5	Individual	Neurofibromatosis				

115	Bezlotoxumab	C	Antibacterial Drugs		Individual	for prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence	Not routinely commissioned	NICE TA601	<a href="https://www.nice.org.uk/guidance/ta601">https://www.nice.org.uk/guidance/ta601</a>	NICE is unable to make a recommendation because the manufacturer did not provide an evidence submission.
116	Bictegravir	N	AIDS/HIV antiretrovirals	5.3.1	Individual					NHSE V15 lists a combination with emtricitabine and tenofovir alafanamide
117	Bimagrumab	N	Cytokine modulators		Group	Myopathy sporadic inclusion body myositis (sIBM) - first-line				
118	Biotin	N	Enzymes	9.6	Individual	Multiple Sclerosis				
119	Blisibimod	N	Cytokine modulators	10.1.3	Group	Systemic lupus erythematosus				
120	Boceprevir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				proposed for removal from national list
121	Bortezomib	N	Antineoplastic drugs	8.1.5	Individual	Cancer				
122	Bortezomib	N	Antineoplastic drugs	8.1.5	Individual	Organ rejection post kidney transplant				Added to match NHSE s/sheet
123	Bosentan	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary hypertension				
124	Bosentan	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Digital ulcers				
125	Bosutinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
126	Botulinum toxin	C	Torsion Dystonias and other involuntary movements	4.9.3	Group	Prevention of headaches in chronic migraine.	Monitored	Migraine only: NICE TA260	<a href="http://guidance.nice.org.uk/TA260">http://guidance.nice.org.uk/TA260</a>	
127	Botulinum toxin	C	Torsion Dystonias and other involuntary movements	4.9.3	Group	Hyperhidrosis	Monitored	GM	When used in line with local GM policy: <i>GM Hyperhidrosis Policy v1.0 Final</i> , available from CCG websites	
128	Botulinum toxin	C	Torsion Dystonias and other involuntary movements	4.9.3	Group	All other uses including torsion dystonias, involuntary movements,	Monitored / Individual Funding	GM	<a href="http://gmmmg.nhs.uk/docs/guidance/Botulinum-toxin-guidance-3-0-Jan20.pdf">http://gmmmg.nhs.uk/docs/guidance/Botulinum-toxin-guidance-3-0-Jan20.pdf</a>	Please check local GM document. However, this has not been adopted as policy.
129	Botulinum toxin	N	Torsion Dystonias and other involuntary movements	4.9.3	Group	Focal spasticity in children				
130	Botulinum toxin	N	Torsion Dystonias and other involuntary movements	4.9.3	Group	Intravesical use in spinal cord injury				
131	Brimapitide	N	Protein kinase inhibitors	12	Group	For acute sensorineural hearing loss (ASNHL)				Intratympanic administration.
132	Brincidofovir	N	Cytomegalovirus infection	5.3.3.2	Individual	In allogeneic haematopoietic stem cell transplant				
133	Brodalumab	C	Immunomodulating drugs	13.5.3	Individual	Psoriasis [IL-17 receptor blocker]	Monitored	NICE TA511	<a href="https://www.nice.org.uk/guidance/ta511">https://www.nice.org.uk/guidance/ta511</a>	
134	Brolucizumab	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Neovascular (wet) age-related macular degeneration (AMD)	Not routinely commissioned			NICE TA in development but paused 04/20

135	Burosumab	N	Cytokine modulators	6.6	Group	For X-linked hypophosphataemia with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons				
136	C1 Esterase inhibitor	N	Allergic Emergencies	3.4.3	Individual	Acute attack and prophylactic treatment of hereditary angiodema				NHSE V15 splits into 3 different rows
137	Cabotegravir	N	AIDS/HIV antiretrovirals	5	Group					
138	Calcifediol	N*	Other endocrine drugs	9.5.1	Group	Secondary hyperparathyroidism in chronic kidney disease				While PSS 9 defines 'complex' hyperparathyroidism, NHSE V15 commissions cinacalcet for undefined hyperparathyroidism and by logical extension, the same should apply here. Only excluded when used for renal dialysis patients
139	Calcifediol	N	Other endocrine drugs	9.5.1	Group	Inbuilt errors in primary bile acid synthesis				In NHSE15 (which spells it incorrectly) for this indication although not in SPS for this
140	Canakinumab	C	Immunomodulating drugs	8.2.4	Individual	Treating gouty arthritis attacks and reducing the frequency of subsequent attacks	Not routinely commissioned	NICE TA281	<a href="http://guidance.nice.org.uk/TA281">http://guidance.nice.org.uk/TA281</a>	NICE TAG terminated - unable to recommend use
141	Canakinumab	N	Immunomodulating drugs	8.2.4	Individual	Autoimmune disorders [e.g. CAPS, MWS, NOMID, CINCA, FCAS, FCU]				
142	Canakinumab	N	Immunomodulating drugs	8.2.4	Individual	Juvenile arthritis				
143	Cannabidiol	N	Cannabinoids	4.8	individual	antiepileptic				'as Epidiolex' states NHSE V15
144	Caplacizumab	N	Platelet Disorder Drugs	9.1.4	Group	Acquired thrombotic thrombocytopenic purpura (aTTP)				included in V15
145	Carglumic acid	N	Drugs used in Metabolic disorders	9.8.1	Individual	Urea cycle disorders, Hyperammonaemia				
146	Carnitine	N	Drugs used in Metabolic disorders	9.8.1	Group	Carnitine deficiency				
147	Caspofungin	N	Antifungals	5.2.4	Individual					
148	Cenegermin	N		11.8	individual	neurotrophic keratitis				
149	Ceralifimod	N			Group	Multiple sclerosis (MS)				not in SPS; drug development cancelled. Included here to match national list.
150	Cerliponase alfa	N	Central Nervous System		Individual	Neuronal ceroid lipofuscinosis - late infantile type 2 (CLN2), a form of Batten disease				
151	Certolizumab Pegol	N	Cytokine modulators	10.1.3	Group	Any paediatric use				N.B. Not on NHSE V14 or V15 but was on V13 for this indication and is still PbRe!

152	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, rheumatology,	Monitored	NICE TA375 / GM Harmonised biologics pathway	<a href="http://www.nice.org.uk/guidance/ta375">http://www.nice.org.uk/guidance/ta375</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf</a>	
153	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis: for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor	Monitored	NICE TA415	<a href="https://www.nice.org.uk/guidance/ta415">https://www.nice.org.uk/guidance/ta415</a>	
154	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	NICE TA383 / GM Harmonised Pathway for biologics in AS and PsA.	<a href="http://guidance.nice.org.uk/TA383">http://guidance.nice.org.uk/TA383</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	
155	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Psoriatic arthritis	Monitored	GM Harmonised Pathway for biologics in AS and PsA.	<a href="https://www.nice.org.uk/guidance/ta445">https://www.nice.org.uk/guidance/ta445</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	
156	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Psoriasis	Monitored	NICE TA574	<a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a> <a href="https://www.nice.org.uk/guidance/ta574">https://www.nice.org.uk/guidance/ta574</a>	link to updated GMMMG Psoriasis biologics pathway added
157	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Crohn's Disease, gastroenterology	Not routinely commissioned			certolizumab not referenced in any NICE CG for inflammatory bowel disease.
158	Cetuximab	N	Antineoplastic drugs	8.1.5	Individual	Cancer				
159	Chenodeoxycholic acid	N	Drugs used in Metabolic disorders		Group	Cerebrotendinous xanthomatosis Primary Biliary Cirrhosis				A lipid storage disorder. For non-chemotherapy indications. Only excluded when used for a metabolic disorder.
160	Cholic acid	N	Drugs used in Metabolic disorders	none	Group	Inborn errors in primary bile acid synthesis				Only excluded when used for a metabolic disorder.
161	Cidofovir	N	Antiviral drugs	5.3.2.2	Group	Cytomegalovirus infections				
162	Cinacalcet	N	Other endocrine drugs	9.5.1.2	Group	primary and secondary hyperparathyroidism				
163	Ciprofloxacin inhalation	N	Antibacterial Drugs	5.1.12	Individual	Bronchiectasis				Only when given by inhalation / nebulisation.
164	Ciprofloxacin liposomal	N	Antibacterial Drugs	5.1.12	Individual	Bronchiectasis				Only when given by inhalation / nebulisation.
165	Cladribine	N	Immunomodulating drugs	8.1.3	Group	Multiple Sclerosis				
166	Cladribine	N	Immunomodulating drugs	8.1.3	Group	Pulmonary Langerhans histiocytosis				
167	Clazakizumab	N	Cytokine modulators	10.1.3	Group	antibody-mediated rejection				
168	Cobicistat	N	AIDS/HIV antiretrovirals		Group	HIV in combination with other anti-retroviral drugs				
169	Cobitolimod	C	Drugs affecting the immune response		Group	Ulcerative colitis (UC) refractory, 3rd line	Not routinely commissioned			Still under development

170	Co-careldopa internal tube intestinal gel	N	Neurodegenerative conditions	4.9.1	Individual	Advanced parkinsons (via PEG)				only when used as intestinal gel with internal tube
171	Colistimethate sodium	N	Antibacterial Drugs	5.1.7	Individual	Management of cystic fibrosis				
172	Collagenase (outpatient use only)	C	Enzymes	10.1.3	Individual	Dupytren's contracture	Monitored	NICE TA 459	<a href="https://www.nice.org.uk/guidance/ta459">https://www.nice.org.uk/guidance/ta459</a>	Use in line with NICE / GM policy. NB: product no longer available. No alternative collagenase identified. Retained here as on national list.
173	Collagenase (outpatient use only)	C	Enzymes	10.1.3	Individual	Frozen Shoulder / Peyronie's Disease / any other use	Not routinely commissioned			Any other use that's not Dupytren's in line with GM policy NB: product no longer available. No alternative collagenase identified. Retained here as on national list.
174	Conestat alfa (Recombinant C1 Esterase inhibitor)	N	Allergic Emergencies	3.4.3	Group	Acute attack of hereditary angiodema				
175	Crizanlizumab	N	Immunomodulating drugs	9.1.3	Group	Sickle cell pain crisis (SCPC)				
176	Crizotinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
177	Darvadstrocel (CX601, Alofisel)	C	Drugs affecting the immune response	1.5.3	Individual	Perianal fistulas in Crohn's Disease	Not routinely commissioned	NICE TA 556	<a href="https://www.nice.org.uk/guidance/ta556">https://www.nice.org.uk/guidance/ta556</a>	Allogeneic, expanded, adipose-derived stem cells. Negative NICE TA 556. Listed here as national list uses CX601
178	Cyclic pyranopterin monophosphate	N	Drugs used in Metabolic disorders	9.8.1	Group	Metabolic disease molybdenum cofactor deficiency (MoCD) Type A				
179	Cysteamine bitartrate (also known and shown as mercaptamine)	N	Drugs used in Metabolic disorders	9.8.1	Individual	Nephropathic cystinosis				
180	Cysteamine hydrochloride	N*	Drugs used in Metabolic disorders	11.1	Individual	Cystinosis [Corneal cystine crystals]				SPS previously said will be NHS England funded (no comment now but PSS 12 includes corneal disorders). <i>Droptcys</i> eye drops (0.1% solution)
183	Dabrafenib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
184	Daclatasvir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Individual	Hepatitis C				proposed for removal from national list. NOT in V15
185	Daclizumab	N	Corticosteroids and other immunosuppressants	8.2	Group	Multiple Sclerosis				Drug withdrawn. Only remains here to match national list and NHSE V15
186	Damoctocog alfa pegol	N*	Fibrinolytics	2.11	Individual	Haemophilia A prophylaxis and treatment				Not on NHSE V11 s/sheet and onwards yet was on V10 and no note. Treatment of haemophilia is commissioned by NHSE.
187	Darbepoetin alfa	N	Drugs used in hypoplastic, haemolytic and renal anaemias	9.1.3	Group	Anaemia associated with chronic renal failure				Only excluded when used in conjunction with renal dialysis ergo NHSE-commissioned. On V15
188	Darunavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
189	Darunavir + cobicistat	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				included to match NHSE list

190	Dasabuvir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
191	Dasatinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
192	Decitabine	N	Myelodysplastic Syndrome	8.1.3	Individual	Cancer				
193	Deferasirox	C	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell: myelodysplastic syndrome	Monitored			CCGs commission use in myelodysplastic syndrome
194	Deferasirox	N	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell				
195	Deferiprone	C	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell: myelodysplastic syndrome	Monitored			CCGs commission use in myelodysplastic syndrome
196	Deferiprone	N	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell				
197	Defibrotide	N	Blood-related products except Fibrin Sealants	none	Group	Hepatic veno-occlusive disease				
198	Delamanid	N	Antituberculosis drugs	5.1.9	Individual	Extensively drug resistant TB				Two rows to match NHSE s/sheet
199	Delamanid	N	Antituberculosis drugs	5.1.9	Individual	Multi drug resistant TB				Two rows to match NHSE s/sheet
200	Desferrioxamine	C	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell: myelodysplastic syndrome	Monitored			CCGs commission use in myelodysplastic syndrome
201	Desferrioxamine	N	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.4	Group	Iron chelation in thalassaemia and sickle cell				
202	Dexamethasone intra-erythrocyte	N*	Immunomodulating drugs	10.1.2.1		Ataxia Teleangiectasia (AT)				ATMP? Being trialled in AT which is NHSE PSS No.1. Not on V15
203	Dexamethasone Intraocular Implant	C	Corticosteroids and other immunosuppressants	11.4.1	Individual	post cataract surgery	Not routinely commissioned			
204	Dexamethasone intravitreal implant	C	Macular Oedema		Individual	Macular oedema secondary to retinal vein occlusion	Monitored	NICE TA229	<a href="http://guidance.nice.org.uk/TA229">http://guidance.nice.org.uk/TA229</a>	
205	Dexamethasone intravitreal implant	C	Macular Oedema		Individual	Diabetic macular oedema	Monitored	NICE TA349	<a href="https://www.nice.org.uk/guidance/ta349">https://www.nice.org.uk/guidance/ta349</a>	
206	Dexamethasone intravitreal implant	C	Macular Oedema		Individual	Inflammation of the posterior segment of the eye presenting as non-infectious uveitis	monitored	NICE TA460	<a href="https://www.nice.org.uk/guidance/ta460">https://www.nice.org.uk/guidance/ta460</a>	

207	Dexrazoxane	N	Immunomodulating drugs	8.1	Group	Anthracycline cardiotoxicity				
208	Dexrazoxane	N	Immunomodulating drugs	8.1	Group	Anthracycline extravasation				
209	Dibotermin alfa	N	Bone morphogenetic protein	none	Individual	Complex spinal injury				rhBMP-2
210	Dibotermin alfa	C	Bone morphogenetic protein	none	Individual	Orthopaedics / other than complex spinal surgery	monitored	GMMMG	<a href="http://gmmmg.nhs.uk/docs/nhs/Dibotermin-alfa-GMMMG-recommendation-for-commissioning-approved-DoCs-Sept-2019.pdf">http://gmmmg.nhs.uk/docs/nhs/Dibotermin-alfa-GMMMG-recommendation-for-commissioning-approved-DoCs-Sept-2019.pdf</a>	new GMMMG position statement for CCG-commissioned uses
211	Dichlorphenamide (Diclofenamide)	N	Neuromuscular Disorders		Individual	for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants (PPP)				A carbonic anhydrase inhibitor previously used in glaucoma but use now seems to be for PPP.
212	Didanosine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
213	Digoxin immune fab	C	Poisoning	16.3.2 (BNF 70)	Individual	Digoxin toxicity	Monitored			
214	Dimethyl fumarate	C	Immunomodulating drugs	13.5	Individual	Dermatology: plaque psoriasis, moderate to severe	Monitored	NICE TA475	<a href="https://www.nice.org.uk/guidance/ta475">https://www.nice.org.uk/guidance/ta475</a>	<a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>
215	Dimethyl fumarate	N	Immunomodulating drugs	8.2.2	Individual	Multiple Sclerosis, neurology				
216	Diroximel fumarate	N	Immunomodulating drugs	8.2.2		Multiple Sclerosis, neurology				
217	Dolutegravir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
218	Domagrozumab	N	Neuromuscular Disorders	10.2	Individual	Duchenne muscular dystrophy				
219	Doravirine	N	AIDS/HIV antiretrovirals	5.3.2	Group	HIV in combination with other anti-retroviral drugs				
220	Dornase alfa	N	Mucolytics	3.7	Individual	Management of cystic fibrosis				
221	Dornase alfa	N	Mucolytics	3.7	Individual	Primary ciliary dyskinesia				Added to match NHSE s/sheet
222	Drisapersen	N	Neuromuscular Disorders	10.2	Individual	Duchenne Muscular Dystrophy				
223	Dupilumab	C	Drugs affecting the immune response		Group	Atopic dermatitis; moderate-to-severe	monitored	NICE TA534	<a href="https://www.nice.org.uk/guidance/ta534">https://www.nice.org.uk/guidance/ta534</a>	CCG funded for those aged 16 and over, treated in the adult service
224	Dupilumab	N	Drugs affecting the immune response		Group	Asthma; persistent, add-on therapy				anti-interleukin-4 receptor (IL-4R) and anti-interleukin-13 receptor (IL-13R) human monoclonal antibody. 2019
225	Ecallantide	N	Allergic emergencies	none	Group	Hereditary angioedema - acute treatment				Entry updated
226	Eculizumab	N	Paroxysmal nocturnal haemoglobinuria	9.1.3	Group	Organ rejection post transplant				Now two rows to match NHSE s/sheet
227	Eculizumab	N	Paroxysmal nocturnal haemoglobinuria	9.1.4	Group	C3 glomerulopathy (post transplant)				Now two rows to match NHSE s/sheet
228	Eculizumab	N	Paroxysmal nocturnal haemoglobinuria	9.1.3	Group	Atypical hemolytic uremic syndrome				
229	Eculizumab	N	Paroxysmal nocturnal haemoglobinuria	9.1.3	Group	Paroxysmal nocturnal haemoglobinuria				
230	Edasalonexent	N	Neuromuscular Disorders	8.2	Individual	Duchenne Muscular Dystrophy				

231	Edratide	N	Drugs affecting the immune response	8.2	Group	systemic lupus erythematosus (SLE)				Not in SPS
232	Efavirenz	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
233	Efraloctocog alfa	N	Platelet Disorder Drugs		Group	Haemophilia A				NHSE V15 also states efmoroctocog alfa / Factor VIII FC fusion protein in its entry for this drug
234	Eftrenonacog alfa	N	Platelet Disorder Drugs	2.11	Group	Haemophilia B				spelling error in national list
235	Elbasvir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
236	Eliglustat	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Gaucher's Disease				
237	Elosulfase alfa	N	Lysosomal Storage Disorder drugs	none	Individual	Mucopolysaccharidosis IV type A				
238	Eltrombopag	C	Platelet Disorder Drugs	9.1.4	Individual	Chronic Immune Thrombocytopenic purpura (ITP)	Monitored	NICE TA293	<a href="http://guidance.nice.org.uk/TA293">http://guidance.nice.org.uk/TA293</a>	While eltrombopag and romiplostim are the responsibility of CCGs regardless of the cause of the thrombocytopenia in adults, paediatrics are NHSE responsibility.
239	Eltrombopag	C	Platelet Disorder Drugs	9.1.5	Individual	Chronic Immune Thrombocytopenic purpura (ITP)	Monitored	NICE TA294		Additional row to match NHSE V15 which notes paediatrics are NHSE responsibility.
240	Eltrombopag	C	Platelet Disorder Drugs	9.1.4	Individual	Severe aplastic anaemia refractory to immunosuppressive therapy	Not routinely commissioned	NICE TA382	<a href="http://www.nice.org.uk/guidance/ta382">http://www.nice.org.uk/guidance/ta382</a>	Terminated NICE appraisal. New row to account for additional licensed indication.
241	Elvitegravir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
242	Elvucitabine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
243	Emapalumab	N				Primary haemophagocytic lymphohistiocytosis (HLH)				
244	Emicizumab	N	Blood-related products		Group	Haemophilia A				
245	Emricasan	N			Group	Hepatitis C infection liver fibrosis after liver transplant				
246	Emtricitabine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				duplicate entry on national list. NHSE V15 also lists many combinations with other anti-retroviral drugs
247	Enfuvirtide	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
248	Entecavir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis B				
249	Enzalutamide	N	Hormone antagonists [not official PbR category]	8.3.4.2		Cancer				Added to match NHSE s/sheet
250	Entolimod	C?	Drugs affecting the immune response	16	Individual	Acute radiation syndrome (ARS)	Not routinely commissioned			UK filing withdrawn. Not on NHSE V15 but SPS thinks would be NHSE commissioned

251	Epoetin alfa, beta, theta and zeta	N	Drugs used in hypoplastic, haemolytic and renal anaemias	9.1.3	Group	Anaemia associated with chronic renal failure				Only excluded when used in conjunction with renal dialysis ergo NHSE-commissioned
252	Epoprostenol	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.8.1	Individual	Pulmonary Arterial Hypertension				Use in vascular disease is commissioned by NHSE within specialist centres. All other indications are CCG commissioned [ref. NHSE]
253	Epratuzumab	N	Cytokine modulators	10.1.3	Group	CD22 antigen inhibitor for Systemic lupus erythematosus (SLE)				
254	Eprodisate	N	Drugs used in hypoplastic, haemolytic and renal anaemias	9.1	Group	Amyloidosis				While NHSE commissions diagnostic service for patients with amyloidosis from Highly Specialist Amyloidosis centres, CCGs commission most treatments [PSS 46]. However NHSE states that it is responsible commissioner for this drug, although it is not routinely commissioned and therefore requires IFRs submitting to NHSE
255	Eptinezumab	C	Immunomodulating drugs	4.7.4.2	Group	Migraine prophylaxis	Not routinely commissioned			intravenous infusion Not on NICE's agenda
256	Eptotermin alfa	N	Bone morphogenetic protein	none	Group	Complex spinal injury				rhBMP-7. No longer licensed.
257	Eptotermin alfa	C	Bone morphogenetic protein	none	Group	Orthopaedics / other than complex spinal surgery	Not routinely commissioned			
258	Erenumab	C	Immunomodulating drugs	4.7.4.2	Group	Migraine prophylaxis	Not routinely commissioned			NICE TA in development
259	Erlotinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
260	Etanercept	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)		TA 455 or as per adult TA's (TA103, TA375, TA143, TA199)		
261	Etanercept	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis			<a href="http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf">http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf</a>	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
262	Etanercept	C	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	NICE TA383 / GM Harmonised Pathway for biologics in AS and PsA.	<a href="http://guidance.nice.org.uk/TA383">http://guidance.nice.org.uk/TA383</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG%20AS%20PsA%20pathway%20v4%20FINAL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG%20AS%20PsA%20pathway%20v4%20FINAL.pdf</a>	
263	Etanercept	C	Cytokine modulators	10.1.3	Group	Psoriasis (plaque)	Monitored	NICE TA103	<a href="http://guidance.nice.org.uk/TA103">http://guidance.nice.org.uk/TA103</a>	
264	Etanercept	C	Cytokine modulators	10.1.3	Group	Psoriasis (plaque) - sequential use of biologic agents	Monitored	GMMMG	<a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>	

265	Etanercept	C	Cytokine modulators	10.1.3	Group	Psoriatic Arthritis	Monitored	NICE TA199 / GM Harmonised Pathway for biologics in AS and PsA.	<a href="http://guidance.nice.org.uk/TA199">http://guidance.nice.org.uk/TA199</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf</a>	
266	Etanercept	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of conventional DMARDs	Monitored	NICE TA375 / GM Harmonised biologics pathway	<a href="http://www.nice.org.uk/guidance/ta375">http://www.nice.org.uk/guidance/ta375</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf</a>	
267	Etanercept	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, if rituximab contra-indicated, or as monotherapy if rituximab and methotrexate contra-indicated	Monitored	NICE TA195 / GM Harmonised biologics pathway	<a href="http://guidance.nice.org.uk/TA195">http://guidance.nice.org.uk/TA195</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf</a>	
268	Etanercept	C	Cytokine modulators	10.1.3	Group	All other adult indications	Not routinely commissioned			
269	Etelcalcetide	N	Other endocrine drugs	9.5.1.2	Group	Hyperparathyroidism				on NHSE V15; dialysis patients only
270	Eteplirsen	N	Neuromuscular disorders		Individual	Duchenne muscular dystrophy; amenable to exon 51 skipping				
271	Etravirine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
272	Etrolizumab	C	Drugs affecting the immune response	1.5.3	Group	Ulcerative colitis (UC) naive to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment	Not routinely commissioned			SPS says filings now not expected until 2021 or later. NHSE states on V11 that it will be responsible for paediatric indications should a positive NICE TA become available for adult indications.
273	Etrolizumab	C	Drugs affecting the immune response	1.5.3	Group	Crohn's disease moderate-to-severe	Not routinely commissioned			
274	Everolimus <i>Afinitor</i>	N	Protein kinase inhibitors	8.1.5	Group	Cancer				
275	Everolimus <i>Certican</i>	N	Protein kinase inhibitors		Group	Preventing organ rejection in heart and liver transplantation				Added to match NHSE s/sheet
276	Everolimus <i>Votubia</i>	N	Protein kinase inhibitors	8.1.5	Group	Subependymal giant cell astrocytoma (SEGA)				
277	Everolimus <i>Votubia</i>	N	Protein kinase inhibitors	8.1.5	Group	Seizures associated with SEGA				
278	Everolimus <i>Votubia</i>	N	Protein kinase inhibitors	8.1.5	Group	Renal angiomyolipoma associated with tubular sclerosis				
279	Evinacumab	N	Lipid regulating drugs	2.12	Group	Homozygous familial hypercholesterolemia				on NHSE V15
280	Evolocumab	C	Lipid regulating drugs	2.12	Group	Hypercholesterolaemia	Monitored	NICE TA394	<a href="https://www.nice.org.uk/guidance/ta394">https://www.nice.org.uk/guidance/ta394</a>	
281	Evolocumab	N	Lipid regulating drugs	2.12	Group	Homozygous familial hypercholesterolaemia				

282	Ex-vivo expanded autologous human corneal epithelial cells containing stem cells 1 <i>Holoclar</i>	N		ATMP	Individual	Orphan market exclusivity for "Treatment of corneal lesions, with associated corneal (limbal) stem cell deficiency, due to ocular burns"				Treatment of adult patients with moderate to severe limbal stem cell deficiency (defined by the presence of superficial corneal neovascularisation in at least two corneal quadrants, with central corneal involvement, and severely impaired visual acuity), unilateral or bilateral, due to physical or chemical ocular burns.
283	Factor IX	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
284	Factor VII	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
285	Factor VIIa (Eptacog alfa)	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
283	Factor VIII	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
284	Factor VIII inhibitor bypassing factor	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
285	Factor XIII	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
286	Fampridine	N	Neuromuscular Disorders	10.2.1	Individual	Multiple Sclerosis				
287	Fasinumab	C	Cytokine Modulators	4.7	Group	Osteoarthritis	Not routinely commissioned			
288	Fedratinib	N	Drugs affecting the immune response		Group	Myelofibrosis				on NHSE V15
289	Fenfluramine	N	Central Nervous System		Individual	Dravet syndrome				on NHSE V15
290	Fibrinogen	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
291	Fibroblast growth factor 1 gene therapy	N	Somatostatin Analogues	None	Group					

292	Fidaxomicin <i>Dificlir</i>	C	Antibacterial Drugs	5.1.7	Individual	Treatment of Clostridium difficile infections (CDI)	Monitored	GMMMG	<a href="http://gmmmg.nhs.uk/docs/nhs/Fidaxomicin-GMMMG-Commissioning-Statement-Final-for-web.pdf">http://gmmmg.nhs.uk/docs/nhs/Fidaxomicin-GMMMG-Commissioning-Statement-Final-for-web.pdf</a>	
291	Filgotinib	C	Drugs affecting the immune response	1.5.3	Individual	Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's Disease	Not routinely commissioned			JAK inhibitor Still in development
294	Fingolimod	N	Immunomodulating drugs	8.2.4	Individual	Multiple Sclerosis				
295	Fitusiran	N	Blood-related products	2.11	Individual	Moderate-to-severe haemophilia A and B				
296	Fluocinolone acetonide intravitreal implant	C	Macular Oedema	11.4.1	Individual	Treatment of diabetic macular oedema	Monitored	NICE TA301	<a href="http://guidance.nice.org.uk/TA301">http://guidance.nice.org.uk/TA301</a>	
297	Fluocinolone acetonide intravitreal implant	C	Macular Oedema	11.4.1	Individual	Treatment of non-infectious uveitis	Monitored	NICE TA590	<a href="http://guidance.nice.org.uk/TA590">http://guidance.nice.org.uk/TA590</a>	
298	Fluocinolone acetonide intravitreal implant	C	Macular Oedema	11.4.1	Individual	Treatment of diabetic macular oedema in phakic eyes	Not routinely commissioned	NICE TA613	<a href="http://guidance.nice.org.uk/TA613">http://guidance.nice.org.uk/TA613</a>	Negative NICE TA
299	Fomepizole	C	Poisoning	none	Individual	Emergency treatment of poisoning >Other poisons >Ethylene glycol and methanol >Fomepizole	Monitored		In line with recommendations from National Poisons Information Service <a href="http://www.npis.org/">http://www.npis.org/</a>	
300	Forigerimod acetate <i>Lupuzor</i>	N	Drugs affecting the immune response		Individual	Systemic lupus erythematosus (SLE)				
301	Fosamprenavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
302	Foscarnet	N	Cytomegalovirus infection	5.3.2.2	Individual	Cytomegalovirus infection				
303	Fostamatinib disodium	C	Protein kinase inhibitors	9.1	Individual	Idiopathic thrombocytopenic purpura (ITP)	Not routinely commissioned			Likely indication is CCG-commissioned. Spleen tyrosine kinase (Syk) inhibitor. SPS suggests NHSE but not on V15
304	Fostemsavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV infection				
305	Fremanezumab	C	Immunomodulating drugs	4.7.4.2	Group	Migraine prophylaxis	Not routinely commissioned			NICE TA in development. Positive FAD, category will move to monitored on issue of TA
306	Galcanezumab	C	Cytokine modulators	4.7.4.2	Group	Cluster headache; chronic and episodic; prevention	Not routinely commissioned			NICE TA in development
307	Galcanezumab	C	Cytokine modulators	4.7.4.2	Group	prevention of episodic migraine	Not routinely commissioned			NICE TA in development
308	Galsulfase	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Mucopolysaccharidosis VI [6 = Matoteaux-Lamy syndrome]				
309	Galunisertib	N	Myelodysplastic Syndrome	8.1.5	Group	Myelodysplastic Syndromes				On NHSE V15. Development discontinued
310	Ganciclovir	N	Cytomegalovirus infection	5.3.2.2	Group	Cytomegalovirus infection				
311	Ganetespib	N	Immunomodulating drugs	8.2.4	Individual	Non-small cell lung cancer (NSCLC) and acute myeloid leukaemia (AML)				
312	Gantenerumab	C	Drugs for dementia	4.11	Group	Alzheimer's disease	Not routinely commissioned			still under development

313	Gefitinib	N	Protein kinase inhibitors	8.1.5	Group	Cancer				
314	Gevokizumab	N	Immunomodulating drugs	11.4.2 / 6.1.2.3	Group	Antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). Uveitis, T2 diabetes?				SPS entry blank 05/20. Commissioner would be dependent on indication. On NHSE V15 for uveitis
315	Givosiran	N	Drugs used in Metabolic disorders	9.8	Group	Acute hepatic porphyrias				
316	Glatiramer acetate	N	Immunomodulating drugs	8.2.4	Group	Multiple Sclerosis, neurology				
317	Glecaprevir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus		Individual	Hepatitis C				
318	Glucarpidase	N	Poisoning	None	Group	For the urgent treatment of methotrexate-induced renal dysfunction				NHSE has commissioning policy B15/P/a
319	Glycerol phenylbutyrate	N	Drugs used in Metabolic disorders	9.8.1	Group	Urea cycle disorders - hyperammonaemia in adults and children ≥2 months of age				
320	Golimumab	N	Cytokine modulators		Group	Any paediatric use		As per adult TAs	<a href="http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf">http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf</a>	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
321	Golimumab	C	Cytokine modulators		Group	Ankylosing spondylitis	Monitored	NICE TA497	<a href="http://guidance.nice.org.uk/TA497">http://guidance.nice.org.uk/TA497</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	reference to AS/ PsA pathway updated
322	Golimumab	C	Cytokine modulators		Group	Psoriatic arthritis	Monitored	NICE TA220 / GM Harmonised Pathway for biologics in AS and PsA.	<a href="http://guidance.nice.org.uk/TA220">http://guidance.nice.org.uk/TA220</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	
323	Golimumab	C	Cytokine modulators		Group	Rheumatoid arthritis (Methotrexate naïve)	Monitored	NICE TA375	<a href="http://www.nice.org.uk/guidance/ta375">http://www.nice.org.uk/guidance/ta375</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf</a>	
324	Golimumab	C	Cytokine modulators		Group	Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs)	Monitored	NICE TA375	<a href="http://www.nice.org.uk/guidance/ta375">http://www.nice.org.uk/guidance/ta375</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf</a>	
	Gosuranemab	N	Central Nervous System		Individual	Supranuclear palsy				on NHSE V15
326	Grazoprevir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				Will be a combination product with elbasvir.
327	Grazoprevir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				is repeated in national list with hep C as 2nd indication

328	Guselkumab	C	Drugs affecting the Immune response	13.5.3	Individual	psoriasis	Monitored	NICE TA521	<a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>	
329	Haem arginate	N	Drugs used in Metabolic disorders	9.8.2	Group	Acute porphyria				
330	Halofuginone	N*	Neuromuscular Disorders		Individual	Duchenne muscular dystrophy				Not on V15 but NHSE is the responsible commissioner for e.g. ataluren in Duchenne Muscular Dystrophy
331	HIV vaccine	N		14	Group	HIV				
332	Human alpha1-proteinase inhibitor	N	Drugs used for emphysema							
333	Human Heterologous Liver Cells	N	Drugs used in Metabolic disorders	9.8.1	Individual	Urea cycle disorders in children				
334	Human Parathyroid hormone-related protein analogue	C	Drugs affecting bone metabolism	6.6.1	Individual	postmenopausal osteoporosis	Not routinely commissioned			This is abaloparatide (rows 4-6)
335	Human Parathyroid hormone-related protein analogue	N	Drugs affecting bone metabolism	6.6.1	Individual	Male and juvenile osteoporosis				This is abaloparatide (rows 4-6)
336	Hydroxypropyl betadex	N*	Drugs used in Metabolic disorders	9.8	Group	Niemann-Pick disease, type C				In SPS as <i>Adrabetadex</i>
337	Ibalizumab	N	AIDS/HIV antiretrovirals	5.3.1	Individual					
338	Icatibant	N	Allergic Emergencies	3.4.3	Individual	Hereditary angiodema - acute and prophylactic treatment				
339	Idarucizumab	C	Oral anticoagulant reversal agents	2.8.4	Group	For reversal of DOACs	Monitored			Category changed to monitored
340	Idebenone	N	Neuromuscular Disorders	10.2	Individual	Duchenne muscular dystrophy				
341	Idebenone <i>Raxone</i>	N*	Neuromuscular Disorders	11.8	Individual	Visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON).				Not in NHSE V15 s/sheet but expected to commission as NHSE commissions other rare mitochondrial diseases AND NHSE commissions voretigene neparvovec for Lebers. Licensed.
342	Idursulfase	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Mucopolysaccharidosis II [2]				
343	IL6 receptor MAb (SA237, satralizumab)	N	cytokine modulator	8.2.4		Neuromyelitis optica				On NHSE V15 as satralizumab. Duplicate with satralizumab below but two entries on national list.
344	Iloprost (nebulised)	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary hypertension				Use in vascular disease is commissioned by NHSE within specialist centres. All other indications are CCG commissioned [ref. NHSE]
345	Imatinib	N	Protein kinase inhibitors	8.1.5	Group	Cancer				
346	Imatinib	N	Protein kinase inhibitors	8.1.5	Group	Graft versus host disease				
347	Imetelstat	N	Protein kinase inhibitors	8.1.6	Group	myelofibrosis				on NHSE V15

348	Imiglucerase	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Non-neurological manifestations of type I or type III Gaucher's disease.				
	Imlifidase	N				Transplant rejection prevention in HLA-sensitised patients				on NHSE V15
349	Indinavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
350	Inebilizumab	N	Immunomodulating drugs			Neuromyelitis optica				On NHSE V15 for multiple sclerosis but development for this indication appears to be discontinued. SPS says for Neuromyelitis optica - PSS 77
351	Infliximab	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)			<a href="http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf">http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf</a>	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
352	Infliximab	N	Cytokine modulators	10.1.3	Group	Behçet's Syndrome				
353	Infliximab	N	Cytokine modulators	10.1.3	Group	Connective tissue disease - interstitial lung disease				
354	Infliximab	N	Cytokine modulators	10.1.3	Group	Crohn's Disease in children				
355	Infliximab	N	Cytokine modulators	10.1.3	Group	Graft versus host disease				
356	Infliximab	N	Cytokine modulators	10.1.3	Group	Hidradenitis suppurativa				
357	Infliximab	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis				
358	Infliximab	N	Cytokine modulators	10.1.3	Group	Pulmonary Sarcoidosis				
359	Infliximab	N	Cytokine modulators	10.1.3	Group	Renal				
360	Infliximab	N	Cytokine modulators	10.1.3	Group	Uveitis [adult and child]				
361	Infliximab	C	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	NICE TA383 / GM Harmonised Pathway for biologics in AS and PsA.	<a href="http://guidance.nice.org.uk/TA383">http://guidance.nice.org.uk/TA383</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	reference to GMMMG AS/PsA pathway updated
362	Infliximab	C	Cytokine modulators	10.1.3	Group	Psoriasis (plaque)	Monitored	NICE TA134	<a href="http://guidance.nice.org.uk/TA134">http://guidance.nice.org.uk/TA134</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>	reference to GMMMG psoriasis pathway updated
363	Infliximab	C	Cytokine modulators	10.1.3	Group	Psoriasis (plaque) - sequential use of biologic agents	Monitored	GMMMG	<a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>	reference to GMMMG psoriasis pathway updated
364	Infliximab	C	Cytokine modulators	10.1.3	Group	Psoriatic Arthritis	Monitored	NICE TA199 / GM Harmonised Pathway for biologics in AS and PsA.	<a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4-2a.pdf</a>	reference to GMMMG AS/ PsA pathway updated
365	Infliximab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of conventional DMARDs	Monitored	NICE TA375 / GM Harmonised biologics pathway	<a href="http://www.nice.org.uk/guidance/ta375">http://www.nice.org.uk/guidance/ta375</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf</a>	reference to GMMMG RA pathway updated

									http://guidance.nice.org.uk/TA195	
366	Infliximab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, if rituximab contra-indicated	Monitored	NICE TA195	http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf	reference to GMMMG RA pathway updated
367	Infliximab	C	Cytokine modulators	10.1.3	Group	Crohn's Disease, gastroenterology	Monitored	NICE TA187	<a href="http://guidance.nice.org.uk/TA187">http://guidance.nice.org.uk/TA187</a>	
368	Infliximab	C	Cytokine modulators	10.1.3	Group	Moderately to severely active ulcerative colitis after the failure of conventional therapy	Monitored	NICE TA329	<a href="http://www.nice.org.uk/guidance/ta329">http://www.nice.org.uk/guidance/ta329</a>	New row inserted for this indication for clarity.
369	Infliximab	C	Cytokine modulators	10.1.3	Group	Acute exacerbations of ulcerative colitis	Monitored	NICE TA163	<a href="http://guidance.nice.org.uk/TA163">http://guidance.nice.org.uk/TA163</a>	
370	Infliximab	C	Cytokine modulators	10.1.3	Group	Moderate to severely active ulcerative colitis	Monitored	NICE TA329	<a href="http://www.nice.org.uk/guidance/ta329">http://www.nice.org.uk/guidance/ta329</a>	
371	Infliximab	C or N, seek guidance if necessary	Cytokine modulators	10.1.3	Group	All other indications	Not routinely commissioned			
372	Inotersen	N			Individual	Familial amyloid polyneuropathy in hereditary TTR amyloidosis				
373	Interferon alfa	N	Immunomodulating drugs	8.2.4	Individual	Hepatitis B+C				
374	Interferon alpha-n3	C	Immunomodulating drugs	8.2.4		genital warts	Not routinely commissioned			
375	Interferon alpha-n3	N	Immunomodulating drugs	8.2.4		Middle East respiratory syndrome				NHSE V15 shows this indication
376	Interferon beta	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis				
377	Intravenous human normal immunoglobulins	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
378	Invertase	N*	Drugs used in Metabolic disorders	9.8.1	Group					NHSE PSS 62 / disaccharide intolerance listed in Service Spec E06
379	Isavuconazole	N	Antifungals	5.2	Individual	Fungal infection				
380	Ivacaftor	N	Mucolytics	3.7	Individual	Management of cystic fibrosis				
381	Ixazomib	N	Drugs used in hypoplastic, haemolytic and renal anaemias	8.1.5	Group	Multiple myeloma (MM) / amyloidosis				
382	Ixekizumab	C	Cytokine modulators	13.5.3	Group	Psoriasis	Monitored	NICE TA442	<a href="https://www.nice.org.uk/guidance/ta442">https://www.nice.org.uk/guidance/ta442</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>	link to GMMMG psoriasis pathway updated
383	Ixekizumab	C	Cytokine modulators	13.5.3	Group	Psoriatic arthritis	Monitored	NICE TA537	<a href="https://www.nice.org.uk/guidance/ta537">https://www.nice.org.uk/guidance/ta537</a>	Spelling error in drug name <b>continues</b> on latest national lists.
384	Ixekizumab	C	Cytokine modulators	13.5.3	Group	Ankylosing Spondylitis	Not routinely commissioned			NICE TA proposed.

385	Ketorolac with Phenylephrine	C	Retinal disorders/intraocular lens replacement surgery	11.8.2	Individual	Intraocular lens replacement surgery	Not routinely commissioned		Do we need a policy on this? Licensed as Omidria 10 mg/mL + 3 mg/mL concentrate for solution for intraocular irrigation.
386	Lamivudine	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.1	Group	Hepatitis B			
387	Lamivudine	N	AIDS/HIV antiretrovirals		Group	HIV in combination with other anti-retroviral drugs			
388	Lampalizumab	C	Subfoveal choroidal neovascularisation	11.8	Group	Geographic atrophy secondary to <b>dry</b> age-related macular degeneration	Not routinely commissioned		Development discontinued
389	Lanadelumab	N	Allergic emergencies	3.04		Type I and II hereditary angioedema			
390	Lanreotide	N	Somatostatin Analogues	8.3.4.3	Group	Cancer			
391	Lanreotide	N	Somatostatin Analogues	8.3.4.3	Group	Acromegaly			NHSE is the responsible commissioner when somatropin analogues are prescribed in Specialist Centres for indications falling outside NICE guidance.
392	Lanreotide	N	Somatostatin Analogues	8.3.4.3	Group	Congenital hyperinsulinism - children only			
393	Lanreotide	C or N, seek guidance if necessary	Somatostatin Analogues	8.3.4.3	Group	Congenital hyperinsulinism - adults	Not routinely commissioned		NHSE has indicated that the responsible commissioner for this use is the commissioner for the service caring for the patient.
394	Lanreotide	C	Somatostatin Analogues	8.3.4.3	Group	Other than NHSE commissioned indications	Licensed indications: monitored. Unlicensed indications: not routinely commissioned		
395	Lanthanum Carbonate	N	Phosphate binding agents	9.5.2.2	Group				
396	Lapatinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer			
397	Laquinimod	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis			Development discontinued
398	Laronidase	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Non-neurological manifestations of Mucopolysaccharidosis I (1)			
399	Lebrikizumab	C	Allergen Immunotherapy		Group	Atopic dermatitis; moderate-to-severe	Not routinely commissioned		IL-13 inhibitor. In development for atopic dermatitis so CCG commissioned.
400	Lebrikizumab	N	Allergen Immunotherapy		Group	Asthma			on NHSE V15 for this indication
401	Ledipasvir* [and in combination with sofosbuvir]	N*	Viral Hepatitis (B&C) & Respiratory Syncytial Virus		Group	Hepatitis C			not on NHSE V15 but NHSE commissions treatments of hepatitis B and C
402	Lenalidomide	N	Immunomodulating drugs	8.2.4	Individual	Cancer			

403	Lenalidomide	N	Immunomodulating drugs	8.2.4		POEMS syndrome				indications separated; on NHSE V15 for this indication
404	Leronlimab	N				HIV infection treatment and prevention				
405	Letermovir	N	Cytomegalovirus infection		Group	Cytomegalovirus infection				
406	Levodopa + Carbidopa	N	Neurodegenerative Conditions	4.9.1	Individual	Parkinson's Disease				Unique delivery mode (i.e. intestinal gel). Duplicates row 170 (both descriptions present in National List).
407	Levofloxacin (inhaled)	N	Antibacterial Drugs	5.1.12	Individual	Management of cystic fibrosis				when delivered via nebulisation/inhalation
408	Levoketoconazole	N		6.7	Individual	Cushing's Disease (adults)				
409	Liothyronine	C	Other endocrine drugs	6.2.1	Individual	myxoedema coma	Monitored	GMMMG recommendation		Only when administered intravenously
410	Lixivaptan	N	Vasopressin V2 receptor antagonist	6.5.2	Group	Hyponatraemia and other endocrine uses				
411	Lomitapide	N	Lipid regulating Drugs	2.12	Individual	Homozygous familial hypercholesterolemia				
412	Lonafarnib	N	Protein kinase inhibitors		Group	Hepatitis D infection (with ritonavir) and / or cancer				SPS lists both indications although NHSE V15 only lists cancer.
413	Lopinavir with Ritonavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				Combination listed by NHSE
414	Lumacaftor with Ivacaftor	N	Mucolytics		Individual					
415	Luspatercept	N	Myelodysplastic Syndrome		Individual	Beta-thalassaemia				
416	Lusutrombopag <i>Mulpleta</i>	C	Platelet Disorder Drugs		Individual	Thrombocytopenia	Monitored	NICE TA617	<a href="https://www.nice.org.uk/guidance/ta617">https://www.nice.org.uk/guidance/ta617</a>	In adults with chronic liver disease prior to undergoing elective invasive procedures to reduce the need for platelet transfusions.
417	Macimorelin	N	Growth Hormone & growth hormone Receptor Antagonist	6.5	Individual	Growth failure				
418	Macitentan	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual					
419	Mannitol (inhaled)	N	Mucolytics	3.7	Individual	Management of cystic fibrosis.				when delivered via nebulisation/inhalation
420	Maralixibat	N			Group	Allagile Syndrome				
421	Maraviroc	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
422	Maraviroc	N	AIDS/HIV antiretrovirals	5.3.1	Group	natalizumab induced PML				
423	Maribavir	N	Cytomegalovirus infection	3.4	Group	Cytomegalovirus infections - treatment				
424	Masitinib	N	Protein kinase inhibitors	8.1.5	Group	Pancreatic cancer / GIST				
425	Mavrilimumab	N*	Drugs affecting the Immune response	10.1.3	Group	Giant cell arteritis				not in SPS. Manufacturer's website states this is under investigation for GCA in which case commissioner is NHSE (PSS 5)

426	Mecasermin	N	Growth Hormone & growth hormone Receptor Antagonist	6.7.4	Group	Growth failure			
427	Mepolizumab	N	Allergen Immunotherapy	3.4.2	Group	Asthma			
428	Mepolizumab	N*	Allergen Immunotherapy	3.4.3	Group	Churg Strauss syndrome			SPS has this potential use listed too. PSS 5
429	Mepolizumab	C	Allergen Immunotherapy	3.4.4	Group	COPD	Not routinely commissioned		COPD use would be CCG commissioned
430	Mercaptamine (cysteamine)	N	Drugs used in Metabolic disorders	9.8.1	Group	Nephropathic cystinosis			duplicates row 179 but both descriptions present in National list.
431	Metreleptin	N*	Other endocrine drugs	6.7	Individual	Lipodystrophy			SPS lists this use although not in V15
432	Metreleptin	N	Other endocrine drugs	6.7	Individual	Dyslipidaemia			As per entry on V15 although this use is not in SPS
433	Metreleptin	N	Other endocrine drugs	6.7	Individual	Congenital leptin deficiency			New entry on V15 although this use is not in SPS
434	Mexiletine	N	Neuromuscular Disorders		individual	Myotonic disorders in adults			
435	Micafungin	N	Antifungals	5.2.4	Individual	Invasive candidiasis (risk of liver tumours)			
436	Migalastat	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Fabry's disease			
437	Miglustat	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Mild to moderate type I Gaucher's disease, Niemann-Pick type C disease			
438	Momelotinib	N	Protein kinase inhibitors		Group	Myelofibrosis			Now in SPS. Appears to be in development for myelofibrosis. Is on NHSE V15 but for cancer
439	Natalizumab	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis			
440	Nelfinavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
441	Nevirapine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
442	Nexobrid	N*		1.9.4	Individual	for removal of eschar in adults with deep partial- and full-thickness thermal burns			Under NHSE PSS 104 Specialist Burn Services? Not in SPS.
443	Nilotinib	N	Protein kinase inhibitors	8.1.5	Group	Cancer			
444	Nintedanib Vargatef	N	Immunomodulating drugs	8.1.5	Individual	Ovarian cancer			
445	Nintedanib Ofev	N	Immunomodulating drugs	8.1.5	Individual	Idiopathic pulmonary fibrosis			
446	Nintedanib Vargatef	N	Immunomodulating drugs	8.1.5	Individual	Non small cell lung cancer			
447	Nitazoxanide	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	none	Group	Hepatitis C			
448	Nitisinone	N	Drugs used in Metabolic disorders	9.8.1	Group	Hereditary tyrosinemia type 1			
449	Nitisinone	N	Drugs used in Metabolic disorders	9.8.1	Group	Alkaptonuria			
450	Nitric Oxide	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	none	Individual	Pulmonary arterial hypertension			

451	Nusinersen	N	Neurodegenerative Conditions	10.2	Individual	Spinal muscular dystrophy				
452	Obeticholic acid <i>Ocaliva</i>	N	Drugs used in Metabolic disorders	9.8.1	Group	Primary biliary cirrhosis / Non-alcoholic steatohepatitis (NASH)				
453	Ocrelizumab	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis				
454	Ocriplasmin	C	Retinal disorders	11.8.2	Individual	Focal vitreomacular adhesion (VMA)	Monitored	NICE TA297	<a href="http://guidance.nice.org.uk/TA297">http://guidance.nice.org.uk/TA297</a>	
455	Octocog Alfa	N	Platelet Disorder Drugs	2.11	Group	Haemophilia A				
456	Octreolin	N	Growth Hormone & growth hormone Receptor Antagonist	6.5	Group	Acromegaly				
457	Octreotide	N	Somatostatin Analogues	8.3.4.3	Group	Cancer				
458	Octreotide	N	Somatostatin Analogues	8.3.4.3	Group	Acromegaly				NHSE is the responsible commissioner when somatropin analogues are prescribed in Specialist Centres for indications falling outside NICE guidance.
459	Octreotide	N	Somatostatin Analogues	8.3.4.3	Group	Congenital hyperinsulinism [children]				
460	Octreotide	C or N, seek guidance if necessary	Somatostatin Analogues	8.3.4.3	Group	Congenital hyperinsulinism [adults]	Not routinely commissioned			NHSE has indicated that the responsible commissioner for this use is the commissioner for the service caring for the patient.
461	Octreotide	C	Somatostatin Analogues	8.3.4.3	Group	Vomiting in palliative care , Entero-cutaneous fistula High output stoma Refractory diarrhoea	Licensed indications: monitored. Unlicensed indications: not routinely funded except for the indications listed adjacent for which the category is monitored	<a href="http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Ocreotide-gastro-recommendation.pdf">http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Ocreotide-gastro-recommendation.pdf</a>		CCG commissioned for non-cancer use
462	Ofatumumab	N*	Immunomodulating drugs	8.2.3	Individual	Relapsing-remitting multiple sclerosis				SPS lists this use and that in next row. Not in V15 but would be expected to be responsible for commissioning both uses.
463	Ofatumumab	N*	Immunomodulating drugs	8.2.3	Individual	Relapsed chronic lymphocytic leukaemia (CLL) - in combination with fludarabine & cyclophosphamide				
464	Olesoxime	N	Neuromuscular Disorders	10.2	Individual	Cholesterol oxime mitochondrial pore modulator for spinal muscular atrophy.				
465	Olipudase alfa	N	Lysosomal Storage Disorder Drugs	9.8.1	Individual	Acid sphingomyelinase deficiency				on NHSE V15
466	Olokizumab	C	Cytokine modulator	10.1.3	Group	Moderate to severe RA	Not routinely commissioned			

467	Omalizumab	N	Allergen Immunotherapy	3.4.2	Individual	IgE mediated severe asthma all persons 6years+				
468	Omalizumab	C	Allergen Immunotherapy	3.4.2	Individual	Chronic spontaneous urticaria	Monitored	NICE TA339	<a href="http://www.nice.org.uk/guidance/ta339">http://www.nice.org.uk/guidance/ta339</a>	
469	Ombitasvir with Paritaprevir with Ritonavir with Dasabuvir +/- ribavirin	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
470	Osilodrostat	N	Other Endocrine drugs	6.7.3	Group	Cushing's disease				
471	Ozanimod	N	Multiple sclerosis (MS)	8.2	Group	relapsing-remitting				
472	Ozanimod	C	IBD	1.5.3	Group	Moderate-to-severe active ulcerative colitis and moderate-to-severe active Crohn's Disease	Not routinely commissioned			
473	Pacritinib	N	Protein kinase inhibitors	8.1.5	Individual	Myelofibrosis				
474	Palivizumab	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.5	Group	RSV prophylaxis				
475	Palovarotene	N*	Drugs affecting bone metabolism	6.6.1	Individual	Fibrodysplasia ossificans progressiva				in NHSE V15
476	Para - Aminosalicilic acid	N	Antituberculosis drugs	5.1.9	Individual	Tuberculosis				
477	Parathyroid hormone	N	Drugs affecting bone metabolism	6.6.1	Individual	Specialist endocrinology conditions				Additional row added for consistency with NHSE spreadsheet
478	Parathyroid hormone	C	Drugs affecting bone metabolism	6.6.1	Group	Osteoporosis in women	Not routinely commissioned			
479	Parenteral Nutrition (after 14 days or where the patient is receiving TPN prior to admission)	C	Parenteral Nutrition	9.3	Individual	Nutrition: Type I intestinal failure	Monitored			NHSE commissions TPN for intestinal failure types II and III but CCGs will commission TPN for Type I i.e. where the primary medical issue isn't one of sub-optimal bowel function. Further information is provided at the foot of the spreadsheet.
480	Parenteral Nutrition (after 14 days or where the patient is receiving TPN prior to admission)	N	Parenteral Nutrition	10.3	Individual	Nutrition: Types II and III intestinal failure				NHSE commissions TPN for intestinal failure types II and III but CCGs will commission TPN for Type I i.e. where the primary medical issue isn't one of sub-optimal bowel function. Further information is provided at the foot of the spreadsheet.
481	Paricalcitol	N	Other endocrine drugs	9.5.12	Group	hyperparathyroidism				
482	Paritaprevir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
483	Pasireotide	N	Somatostatin Analogues	6.3.4.3	Group	Acromegaly				Two rows to match NHSE s/sheet
484	Pasireotide	N	Somatostatin Analogues	6.3.4.3	Group	Cushing's disease				Two rows to match NHSE s/sheet
485	Patisiran	N		9.8	individual	Hereditary transthyretin amyloidosis				
486	Pazopanib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				

487	Pegbelfermin	C				Non-alcoholic steatohepatitis	Not routinely commissioned			SPS suggests NHSE commissioned but PSS 131 says CCGs commission this and not on NHSE V15
488	Peginterferon alfa	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	8.2.4	Group	Hepatitis B and C				
489	Peginterferon Beta-1a	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis				
490	Pegunigalsidase alfa	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Fabry's disease				
491	Pegvaliase	N	Drugs used in Metabolic disorders	9.8.1	Group	Phenylketonuria				
492	Pegvisomant	N	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Individual	Acromegaly				
493	Pembrolizumab	N	Immunomodulating drugs	8.2.4		cancer indications				N.B. This drug is not in Annex A (nor was it on last year's list) but is included here to match NHSE s/sheet
494	Pembrolizumab	N	Immunomodulating drugs	8.2.4		drug resistant gestational trophoblastic neoplasia				to match NHSE V15
495	Pibrentasvir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3.2	Group	Hepatitis C				SPS lists combination with glecaprevir.
496	Piclidenoson	C	Cytokine modulators	10.1.3	Group	Moderate-to-severe plaque psoriasis / rheumatoid arthritis	Not routinely commissioned			
497	Pirfenidone	N	Pulmonary Fibrosis	3.11	Individual	Idiopathic pulmonary fibrosis				
498	Pitolisant	C	Hypnotics and anxiolytics	4.1.1	Individual	narcolepsy with or without cataplexy	Not routinely commissioned			
499	Platelet lysate-based therapy	C?			Individual	regenerating injured tendons near the surface of the skin e.g. tennis elbow	Not routinely commissioned			
500	Plerixafor	N	Drugs affecting the immune response	9.1.7	Individual	Stem cell mobilisation				
501	Poloxamer 188	N?	Neuromuscular Disorders	10.2	Individual	attenuates membrane damage and cell injury - possible use in chronic microvascular diseases and skeletal muscle deficiencies				Not in SPS nor V15. Suggested commissioner (NHSE) is based on PbR category of neuromuscular disorder but any application for use will have to be checked for likely commissioner
502	Pomalidomide	N	Immunomodulating drugs	8.2.4	Group	Cancer				
503	Pomalidomide	N	Immunomodulating drugs	8.2.4	Group	Myelofibrosis and multiple myeloma				
504	Ponatinib	N	Protein kinase inhibitors	8.1.5	Group	Chronic myelogenous leukaemia (CML), Acute lymphoblastic leukaemia (ALL)				
505	Ponesimod	N	Multiple sclerosis (MS)	10.2	Group	relapsing-remitting multiple sclerosis				

506	Posaconazole	N	Antifungals	5.2.1	Individual	For all invasive fungal infections including those associated with transplants and aspergillosis				Note that treatment of Allergic bronchopulmonary aspergillosis (ABPA) is CCG-commissioned.
507	Pretomanid	N	Antibacterial Drugs	5.1.9	Individual	Tuberculosis				
508	Protein C	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
509	Prothrombin Complex	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
510	Raltegravir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
511	Ranibizumab	C	Subfoveal choroidal neovascularisation	11.8.2	Group	Wet age related macular degeneration, diabetic macular oedema, branch and central retinal vein occlusion, choroidal neovascularisation secondary to pathological myopia	Monitored	NICE TA155 / 274 / 283 / 298	<a href="http://guidance.nice.org.uk/TAxxx">http://guidance.nice.org.uk/TAxxx</a> etc	
512	Rasburicase	N	Gout and cytotoxic-induced hyperuricaemia	10.1.4	Individual	Treatment of acute hyperuricaemia in patients with haematological malignancy				
513	Ravulizumab	N	Paroxysmal nocturnal haemoglobinuria			paroxysmal nocturnal haemoglobinuria				
514	Raxibacumab	N	drugs affecting the immune response	5	Group	Anthrax				
515	Refanalin	N				Renal transplant - prevention of delayed graft function				
516	Regorafenib	N	Protein kinase inhibitors	8.1.5	Group	Cancer				
517	Reloxaliase	C				Adult secondary hyperoxaluria	Not routinely commissioned			Not on NHSE V15 so CCG-commissioned
518	Reltecemod	N*	Immunomodulating drugs	5	Individual	Septic shock (sepsis) due to severe bacterial infections, initially necrotising soft tissue infection CHILDREN				SPS says not being developed for UK market. NOTE that if the sepsis is in a child, treatment is NHSE commissioned (PSS 130), should this drug be licensed or used in a child so I have split the commissioner.
519	Reltecemod	C	Immunomodulating drugs	5	Individual	Septic shock (sepsis) due to severe bacterial infections, initially necrotising soft tissue infection ADULTS	Not routinely commissioned			" policy would be required but only if drug is likely to come to market.

520	Reparixin	N	drugs affecting the immune response	6.1	Individual	Type 1 diabetes mellitus; prevention of delayed graft function after pancreatic islet transplantation				
521	Reslizumab	N	Allergen Immunotherapy	3.4.2	Group	Allergic, eosinophilic asthma				
522	Reveglucosidase alfa	N	Lysosomal Storage Disorder Drugs		Group	Pompe disease				
523	Rigosertib	N	Myelodysplastic Syndrome	8	Individual	Myelodysplastic Syndrome and pancreatic cancer				
524	Rilpivirine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
525	Rimeporide	N	Neuromuscular Disorders	10	Individual	duchenne muscular dystrophy				
526	Rintatolimod	C	Immunomodulating drugs	4	Individual	Chronic fatigue syndrome	Not routinely commissioned			
527	Riociguat	N	Vasodilator antihypertensive drugs/Pulmonary	2.5.1	Individual	Pulmonary arterial hypertension				NHSE V15 also lists chronic thromboembolic pulmonary hypertension (CTEPH)
528	Risankizumab	C	Drugs affecting the immune response	13.5.2	Individual	psoriasis	Monitored	NICE TA 596	<a href="https://www.nice.org.uk/guidance/ta596">https://www.nice.org.uk/guidance/ta596</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>	link to NICE TA and GMMMG Pathway updated
529	Risdiplam	N	Neuromuscular Disorders		Individual	Spinal muscular atrophy				on V15 (if out of alphabetical order)
530	Ritonavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
531	Rituximab	N	Cytokine modulators	10.1.3	Group	ANCA-positive vasculitis				
532	Rituximab	N	Cytokine modulators	10.1.3	Group	Anti-NMDA receptor encephalitis				
533	Rituximab	N	Cytokine modulators	10.1.3	Group	Acquired haemophilia				
534	Rituximab	N	Cytokine modulators	10.1.3	Group	Steroid Sensitive Nephrotic syndrome				clarified as NHSE commissioned in adults too - see PSS Manual Service No.15
535	Rituximab	N	Cytokine modulators	10.1.3	Group	Primary Sjorgen's Syndrome (PSS)				
536	Rituximab	N	Cytokine modulators	10.1.3	Group	Chronic inflammatory demyelinating polyneuropathy				
537	Rituximab	N	Cytokine modulators	10.1.3	Group	Connective tissue disease - interstitial lung disease				
538	Rituximab	N	Cytokine modulators	10.1.3	Group	Graft versus host disease				
539	Rituximab	N	Cytokine modulators	10.1.3	Group	ABO-incompatible kidney transplants				
540	Rituximab	N	Cytokine modulators	10.1.3	Group	Nephritis				
541	Rituximab	N	Cytokine modulators	10.1.3	Group	Neuromyelitis Optica				
542	Rituximab	N	Cytokine modulators	10.1.3	Group	SLE				
543	Rituximab	N	Cytokine modulators	10.1.3	Group	Membranous nephropathy				
544	Rituximab	N	Cytokine modulators	10.1.3	Group	Dermatomyositis and polymyositis (adults)				
545	Rituximab	N	Cytokine modulators	10.1.3	Group	Myasthenia gravis				
546	Rituximab	N	Cytokine modulators	10.1.3	Group	Immunoglobulin G4 related disease				
547	Rituximab	N	Cytokine modulators	10.1.3	Group	Neuromyelitis optica				

548	Rituximab	N	Cytokine modulators	10.1.3	Group	Pemphigus Vulgaris				
549	Rituximab	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis				
550	Rituximab	C	Cytokine modulators	10.1.3	Group	Refractory Primary Idiopathic Immune Cytopenias	Monitored		<a href="http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/GMMM-G-Rituximab-recommendation-final.pdf">http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/GMMM-G-Rituximab-recommendation-final.pdf</a>	Unlicensed. Includes Refractory Idiopathic Thrombocytopenia Purpura (ITP), Autoimmune Haemolytic Anaemia (AIHA) and Evans syndrome.
551	Rituximab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, Rheumatology	Monitored	NICE TA195	<a href="http://guidance.nice.org.uk/TA195">http://guidance.nice.org.uk/TA195</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMM-G-RA-pathway-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMM-G-RA-pathway-v4-1.pdf</a>	
552	Rituximab (IV)	N	Cytokine modulators	10.1.3	Group	Cancer				
553	Rituximab subcutaneous formulation	N	Cytokine modulators	10.1.3	Group	Cancer				
554	Rituximab	C or N, seek guidance if necessary	Cytokine modulators	10.1.3	Group	All other indications	Not routinely commissioned			
555	Rivipansel sodium	N	Platelet Disorder Drugs	9.1	Individual	Sickle cell disease; hepatic veno-occlusive crisis				
556	Romiplostim	C	Platelet Disorder Drugs	9.1.4	Group	Chronic immune thrombocytopenic purpura (ITP)	Monitored	NICE TA221	<a href="http://www.nice.org.uk/guidance/TA221">http://www.nice.org.uk/guidance/TA221</a>	While eltrombopag and romiplostim are the responsibility of CCGs regardless of the cause of the thrombocytopenia in adults, paediatrics are NHSE responsibility.
	Romiplostim	N	Platelet Disorder Drugs	9.1.4	Group	Chronic immune thrombocytopenic purpura (ITP) in children				Commissioners separated to accord with entry in NHSE V15
557	Romozosumab	N*	Immunomodulating drugs		Group	Osteoporosis in men				
558	Romozosumab	C	Immunomodulating drugs		Group	postmenopausal osteoporosis in women	Not routinely commissioned			
559	Ropeginterferon alfa-2b	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus		Group	Hepatitis C, Polycythemia vera				
560	Roxadustat	C	Drugs used in hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (non dialysis-dependent)	Not routinely commissioned			SPS says CCG commissioned.
561	Roxadustat	N	Drugs used in hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (dialysis-induced)				SPS says CCG commissioned but use in dialysis-induced patients is confirmed by V13 to be NHSE.
562	Rurioctocog alfa pegol	N	Blood related products	2.11	Group	Haemophilia A				
563	Ruxolitinib	N	Protein kinase inhibitors	8.1.5	Group	Cancer				
564	Ruzasvir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				SPS says drug discontinued (was a component of a combination product). On NHSE V15
565	Sacrosidase	N	Drugs used in Metabolic disorders	9.8.1	Group	Congenital sucrase-isomaltase deficiency				
566	Sapropterin	N	Drugs used in Metabolic disorders	9.4.1	Group	Hyperphenylalaninaemia (HPA) [adults and children with phenylketonuria]				2 entries to match NHSE list

567	Sapropterin	N	Drugs used in Metabolic disorders	9.4.1	Group	Hyperphenylalaninaemia (HPA) [Maternal phenylketonuria]				2 entries to match NHSE list
568	Saquinavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
569	Sarilumab	C	Cytokine modulators	10.1.3	Group		Monitored	NICE TA485	<a href="https://www.nice.org.uk/guidance/ta485">https://www.nice.org.uk/guidance/ta485</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf</a>	
570	Satralizumab	N	Cytokine modulators	10.1.3	Group	Neuromyelitis optica				
571	Sebelipase alfa	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Lysosomal acid lipase deficiency				
572	Secukinumab	N	Cytokine modulators	13.5.3	Group	Paediatric indications				
573	Secukinumab	C	Cytokine modulators	13.5.3	Group	Psoriasis	Monitored	NICE TA350	<a href="https://www.nice.org.uk/guidance/ta350">https://www.nice.org.uk/guidance/ta350</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>	reference to GMMMG psoriasis pathway updated
574	Secukinumab	C	Cytokine modulators	10.1.3	Group	Psoriatic arthritis	Not routinely commissioned	NICE TA445	<a href="https://www.nice.org.uk/guidance/ta445">https://www.nice.org.uk/guidance/ta445</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	reference to GMMMG AS/ PsA pathway updated
575	Secukinumab	C	Cytokine modulators	10.1.3	Group	Active Ankylosing spondylitis	Monitored	NICE TA407	<a href="https://www.nice.org.uk/guidance/ta407">https://www.nice.org.uk/guidance/ta407</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	reference to GMMMG AS/ PsA pathway updated
576	Selexipag	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary arterial hypertension				
577	Setrusumab	N	Drugs affecting bone metabolism	6.5		osteogenesis imperfecta				On V15
578	Sevelamer	N	Phosphate binding agents	9.5.2.2	Group	Phosphate binding agents				Adult renal dialysis only
579	Siltuximab	N*	Cytokine modulators	8.2.4	Group	Cytokine release syndrome				Tocilizumab for this indication is commissioned by NHSE
580	Simeprevir	N*	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				proposed for removal from national list. Not on V15
581	Siponimod	N	Immunomodulating drugs	8.2.4	Group	Secondary progressive, relapsing and non-relapsing multiple sclerosis				
582	Sirolimus	N	Drugs affecting the immune response	8.2	Individual	Prophylaxis of organ rejection				
583	Sirolimus (in vitreal)	C	Drugs affecting the immune response	8.2.2	Individual	Chronic non-infectious, posterior segment uveitis				NHSE only commissions treatment of uveitis where treatment is systemic or complex. SPS thinks will be CCG commissioned
585	Sirukumab	C	Drugs affecting the immune response	10.1.3	Group	Rheumatoid arthritis	Not routinely commissioned			IL-6 inhibitor. Development discontinued.
586	Sodium oxybate	N	Hypnotics and anxiolytics	4.1.1	Individual	Narcolepsy - paediatric services only				

587	Sodium oxybate	C	Hypnotics and anxiolytics	4.1.1	Individual	Narcolepsy with cataplexy	Not routinely commissioned			All requests to go to CCGs for detailed consideration at IFR Panels
588	Sodium phenylbutyrate	N	Drugs used in Metabolic disorders	9.8.1	Group	Urea cycle disorders				
590	Sofosbuvir / ledipasvir +/- ribavirin	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3.2	Group	Hepatitis C				Entries now match NHSE s/ sheet
591	Sofosbuvir / peginterferon + ribavirin	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3.2	Group	Hepatitis C				Entries now match NHSE s/ sheet
592	Sofosbuvir / velpatasvir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3.3	Group	Hepatitis C				Entries now match NHSE s/ sheet
593	Solanezumab	C	Drugs affecting the immune system	4.11	Individual	Alzheimer's disease	Not routinely commissioned			Not in SPS; drug discontinued?
594	Solriamfetol	C	Hypnotics and anxiolytics	4.1.1	Individual	Obstructive sleep apnoea syndrome (OSAS)-associated excessive daytime sleepiness (EDS)	Not routinely commissioned			
595	Somapacitan	C	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Group	Growth hormone deficiency in adults	Not routinely commissioned			long-acting human growth hormone derivative, designed for once-weekly administration
	Somapacitan	N*	Growth Hormone & growth hormone Receptor Antagonist	6.5.2	Group	Growth hormone deficiency in pre-pubertal children				SPS suggests would be NHSE commissioned for this indication but not on V15
596	Somatogon	C	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Group	Growth hormone deficiency in adults	Not routinely commissioned			long-acting, proprietary formulation of somatropin, for once weekly or bi-monthly administration
597	Somatropin	C	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Group	Growth hormone deficiency children	Monitored	NICE TA188	<a href="http://www.nice.org.uk/guidance/TA188">http://www.nice.org.uk/guidance/TA188</a>	NHSE is the responsible commissioner when prescribed in specialist centres for indications falling outside NICE guidance
598	Somatropin	C	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Group	Severe growth hormone deficiency in adults	Monitored	NICE TA64	<a href="http://www.nice.org.uk/guidance/TA64">http://www.nice.org.uk/guidance/TA64</a>	NHSE is the responsible commissioner when prescribed in specialist centres for indications falling outside NICE guidance
599	Sorafenib	N	Protein kinase inhibitors	8.1.5	Group	Cancer				
600	Stavudine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
601	Subcutaneous human normal immunoglobulins	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
602	Sucroferric oxyhydroxide	N	Phosphate binding agents	9.5.2.2	Group	Phosphate binding agent				adult renal dialysis only
603	Sunitinib	N	Protein kinase inhibitors	8.1.5	Group	Cancer				
	Sutimlimab	N	Drugs used in haemolytic anaemias			Primary Cold Agglutinin Disease				on NHSE V15
604	Tabalumab	N	Cytokine Modulators		Group	SLE				on NHSE V15
605	Tafamidis Vyndaqel	N	Neurodegenerative Conditions		Individual	Amyloidosis; senile, systemic. Cardiovascular disorders; transthyretin cardiomyopathy (TTR-CM)				TTR-CM not on NHSE list but NHSE would be commissioner

606	Taliglucerase alfa	N	Lysosomal Storage Disorder Drugs		Group	Gaucher's disease				
607	Tanezumab	C	Cytokine modulators	4.7	Group	Osteoarthritis	Not routinely commissioned			
608	Taribavirin	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.5	Group	Hepatitis C				
609	Teduglutide	N	Cytokine modulators [GLP-2 analogue]	1	Group	Short bowel syndrome				
610	Telaprevir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				proposed for removal from national list. Not on V15
611	Telbivudine	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis B				
612	Temsirolimus	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
613	Tenofovir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				
614	Tenofovir alafenamide	N	AIDS/HIV antiretrovirals	5.3.1		Hepatitis B				Additional tenofovir entries added to accord with NHSE list
615	Tenofovir alafenamide	N	AIDS/HIV antiretrovirals	5.3.1		HIV				Tenofovir alafenamide is a pro drug of tenofovir designed to undergo conversion to tenofovir intracellularly
616	Tenofovir alafenamide with cobicistat, elvitegravir and emtricitabine	N	AIDS/HIV antiretrovirals	5.3.1		HIV				
617	Tenofovir disoproxil with cobicistat, elvitegravir and emtricitabine		AIDS/HIV antiretrovirals	5.3.1		HIV				
618	Tenofovir with Emtricitabine and Efavirenz	N	AIDS/HIV antiretrovirals	5.3.1		HIV				
619	Tenofovir with emtricitabine and rilpivirine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV				
620	Teprasiran	N	Renal transplantation			Prevention of delayed graft function				on NHS V15
621	Teprotumumab	N	Immunomodulating drugs			Graves orbitopathy				on NHS V15
622	Teriflunomide	N	Immunomodulating drugs	8.2.4	Group	multiple sclerosis				
623	Teriparatide	N	Drugs affecting bone metabolism	6.6.1	Individual	Osteoporosis in men and juveniles Osteogenesis imperfecta				
624	Teriparatide	C	Drugs affecting bone metabolism	6.6.1	Individual	Osteoporosis in women	Monitored	NICE TA161	<a href="http://guidance.nice.org.uk/TA161">http://guidance.nice.org.uk/TA161</a>	
625	Tesamorelin	?	Growth Hormone & growth hormone Receptor Antagonist	13.1	Group	HIV-associated lipodystrophy				SPS says development discontinued.
626	Tetrahydrobiopterin	N	Drugs used in Metabolic disorders	9.4.1	Group	Phenylketonuria				is an alternative name for sapropterin, rows 566/7
627	Tezacaftor	N	Mucolytics	3.7	Group	Cystic Fibrosis				On NHSE list and SPS in combination with ivacaftor and other drugs for CF.
628	Tezepelumab	N	Allergen Immunotherapy	3.4	Group	Asthma - severe				on NHSE V15

629	Thalidomide	N	Immunomodulating drugs	8.2.4	Group	Cancer				
630	Thrombomodulin, Recombinant Human	N	Fibrinolytics	2.10.2	Individual	Septic shock (Sepsis)				on NHSE V15 so commissioner changed. However, reference is to NICE <i>IPG060</i> and <i>IPG 60</i> is thrombin injections for pseudoaneurysm
631	Tildrakizumab	C	Skin Conditions	13.5	Group	Psoriasis	Monitored	NICE TA575	<a href="https://www.nice.org.uk/guidance/ta575">https://www.nice.org.uk/guidance/ta575</a>	
632	Tipranavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				
633	Tobramycin	N	Antibacterial Drugs	5.1.4	Individual	Management of cystic fibrosis				when delivered via nebulisation / inhalation
634	Tocilizumab	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)			<a href="http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf">http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf</a>	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
635	Tocilizumab	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis				
636	Tocilizumab	N	Cytokine modulators	10.1.3	Group	Giant Cell arteritis				
637	Tocilizumab	N	Cytokine modulators	10.1.3	Group	Takayasu arteritis				
638	Tocilizumab	N	Cytokine modulators	10.1.3	Group	Adult onset Still's disease				
638	Tocilizumab	N	Cytokine modulators	10.1.3	Group	Cytokine release syndrome				new indication on NHSE V15
639	Tocilizumab	C	Cytokine modulators	10.1.3	Group	Rheumatoid arthritis	Monitored	NICE TA375 / GM Harmonised biologics pathway	<a href="http://www.nice.org.uk/guidance/ta375">http://www.nice.org.uk/guidance/ta375</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-FINAL-v4-1.pdf</a>	
640	Tofacitinib	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis	Monitored	NICE TA480 / GM Harmonised biologics pathway	<a href="https://www.nice.org.uk/guidance/ta480">https://www.nice.org.uk/guidance/ta480</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf</a>	reference to NICE and GMMMG RA pathway updated
641	Tofacitinib	C	Cytokine modulators	10.1.3, 1.5.4	Group	Ulcerative colitis	Monitored	NICE TA547	<a href="https://www.nice.org.uk/guidance/ta547">https://www.nice.org.uk/guidance/ta547</a>	
642	Tofacitinib	C	Cytokine modulators	10.1.3, 1.5.4	Group	Any other indication in adults than the above	Not routinely commissioned			
643	Tolvaptan <i>Samsca</i>	N	Vasopressin V2 receptor antagonist	6.5.2	Group	Hyponatraemia in cancer				NHS England has stated that it is the responsible commissioner for this drug only when used in this indication.
644	Tolvaptan <i>Samsca</i>	C	Vasopressin V2 receptor antagonist	6.5.2	Group	Hyponatraemia and other endocrine uses including SIADH	Not routinely commissioned			
645	Tolvaptan <i>Jinarc</i>	C	Vasopressin V2 receptor antagonist	6.5.2	Group	Autosomal dominant polycystic kidney disease	Monitored	NICE TA358	<a href="http://www.nice.org.uk/guidance/ta358">http://www.nice.org.uk/guidance/ta358</a>	New row inserted for this indication. CCG commissioned
646	Tralokinumab	N	Allergen Immunotherapy	3.4	Group	Asthma - severe				SPS does not list this use but remains here to match NHSE list
647	Tralokinumab	C	Allergen Immunotherapy	3.4	Group	Atopic dermatitis; moderate-to-severe	Not routinely commissioned			
648	<b>Trenonacog alfa</b>	N	Blood related products		Group	Haemophilia B				NHSE lists this but isn't on national list!

649	Trientine	N	Drugs used in Metabolic disorders		Group	Wilson's Disease				
650	Triheptanoin	N	Drugs used in Metabolic disorders	9.8.1	Group	Long-chain fatty acid oxidation disorders				SPS lists this indication. However, on NHSE list for pyruvate carboxylase deficiency
651	Upadacitinib	C	Drugs affecting the immune response	10.1.3	Group	Rheumatoid arthritis	Not routinely commissioned			various NICE TAs expected. If positive, category will change to monitored.
652	Uprifosbuvir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	hepatitis C				on NHSE V15. SPS says discontinued
653	Uridine triacetate	N	Poisoning	9.8.1	Group	Fluorouracil (5-FU) overexposure or toxicity				In V15 but incorrectly in section dealing with non-PbR exclusions. Also used for hereditary orotic aciduria, an ultra-rare metabolic disorder.
654	Ustekinumab	N	Drugs affecting the immune response	10.3 / 13.5	Group	Paediatric indications (where adult TA available)				On NHSE V15 for plaque psoriasis in children
655	Ustekinumab	C	Drugs affecting the immune response	13.5	Group	Psoriasis (plaque)	Monitored	NICE TA180	<a href="http://guidance.nice.org/TA180">http://guidance.nice.org/TA180</a> GMMMG guidance: <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-High-cost-drugs-pathway-for-psoriasis-v2-18-FNL.pdf</a>	link to GMMMG psoriasis pathway updated
656	Ustekinumab	C	Drugs affecting the immune response	10.3	Group	Psoriatic arthritis	Monitored	NICE TA340	<a href="http://www.nice.org.uk/guidance/ta340">http://www.nice.org.uk/guidance/ta340</a> <a href="http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf">http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf</a>	
657	Ustekinumab	C	Drugs affecting the immune response	1.5	Group	Crohn's Disease	Monitored	NICE TA456	<a href="https://www.nice.org.uk/guidance/ta456">https://www.nice.org.uk/guidance/ta456</a> <a href="http://gmmmg.nhs.uk/docs/guidance/Biologics-pathway-for-Inflammatory-Bowel-Disease-in-Adults-v2-0.pdf">http://gmmmg.nhs.uk/docs/guidance/Biologics-pathway-for-Inflammatory-Bowel-Disease-in-Adults-v2-0.pdf</a>	
658	Ustekinumab	C	Drugs affecting the immune response	1.5	Group	Ulcerative colitis	Monitored	NICE TA633	<a href="https://www.nice.org.uk/guidance/ta633">https://www.nice.org.uk/guidance/ta633</a>	new NICE TA 17.06.20
659	Ustekinumab	C	Drugs affecting the immune response	10.3	Group	Any other use	Not routinely commissioned			
660	Vadadustat	C	Drugs used in hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (non dialysis-dependent)	Not routinely commissioned			Trials found for use in dialysis-dependent patients (NHSE) and non-dialysis-dependent patients (CCG)
661	Vadadustat	N	Drugs used in hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (dialysis-dependent)				Trials found for use in dialysis-dependent patients (NHSE) and non-dialysis-dependent patients (CCG)
662	Valbenazine	C	Torsion Dystonias and other involuntary movements	4	Individual	Tardive Dyskinesia	Not routinely commissioned			
663	Valganciclovir	N	Cytomegalovirus infection	5.3.2.2	Group	CMV retinitis / Prophylaxis CMV +ve donor transplant				

664	Vancomycin	C?	Antibacterial Drugs	5.1.7	Individual						Unique delivery system only - but what? SPS lists a dry powder form in a capsule-based device for CF-associated MRSA lung infections - CCG commissioned?
665	Vandetanib	N	Protein kinase inhibitors	8.1.5	Group	Thyroid cancer					
666	Vapreotide	C	Growth Hormone & growth hormone Receptor Antagonist		Group	Somatostatin analogue for Oesophageal varices	Not routinely commissioned				not in SPS
667	Vatiquinone	N	Neurodegenerative Conditions		Individual	Friedreich's ataxia					not in SPS. On NHSE V15 for this indication
668	Vedolizumab	N	Drugs affecting the immune response	1.5.3	Group	Paediatric indications (where adult TA available)					
669	Vedolizumab	C	Drugs affecting the immune response	1.5.3	Group	Crohn's Disease	Monitored	NICE TA352		<a href="http://www.nice.org.uk/guidance/ta352">http://www.nice.org.uk/guidance/ta352</a>	
670	Vedolizumab	C	Drugs affecting the immune response	1.5.3	Group	Ulcerative colitis	Monitored	NICE TA342		<a href="http://www.nice.org.uk/guidance/ta342">http://www.nice.org.uk/guidance/ta342</a>	
671	Velaglucerase alfa	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Gaucher's disease					
672	Velcalcetide	N	Drugs affecting bone metabolism	6.5	Individual	Hyperparathyroidism					
673	Velmanase alfa	N	Drugs used for treating alpha-mannosidosis			alpha-mannosidosis lysosomal disease					
674	Vemurafenib	N	Protein kinase inhibitors	8.1.5	Group	Melanoma					
675	Verteporfin	C	Subfoveal choroidal neovascularisation	11.8.2	Group	Wet age related macular degeneration (with predominantly classic subfoveal choroidal neovascularisation (CNV)), ophthalmology	Monitored	NICE TA68		<a href="http://guidance.nice.org.uk/TA68">http://guidance.nice.org.uk/TA68</a>	
676	Vestronidase alfa	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Mucopolysaccharidosis VII (MPS VII - Sly disease)					
677	Voclosporin	N*	Drugs affecting the immune response	8.2	Individual	Lupus nephritis - as an adjunct to use with mycophenolate					SPS now suggests CCG commissioned. NOT on NHSE V15 but NHSE does commission other treatments for SLE and this is where it affects the kidneys.
678	Voclosporin	C	Drugs affecting the immune response		Individual	Mild to moderate dry eye syndrome	Not routinely commissioned				new indication shown on SPS which would be CCG commissioned
679	Volanesorsen	N	Lipid regulating Drugs	2.12	Individual	Type 1 hyperlipoproteinaemia (familial chylomicronemia syndrome)					
680	Von Willebrand factor analogue	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)					NHSE V15 still uses "recombinant"
681	Vonicog alfa	N	Blood related products	2.11	Group	Von Willebrand Disease					on NHSE V15

682	Voretigene neparvovec	N	Retinal disorders/intraocular lens replacement surgery	11.8	Individual	inherited retinal dystrophies				
683	Voriconazole	N	Antifungals	5.2.1	Individual	For all invasive fungal infections including those associated with transplants				Note that treatment of Allergic bronchopulmonary aspergillosis (ABPA) is CCG-commissioned.
684	Voriconazole	N	Antifungals	5.2.1	Individual	Chronic pulmonary aspergillosis				
685	Voxelotor	N		9.1	Individual	Sickle cell disease - prophylaxis				
686	VX-210 (Cethrin)	N		4		Traumatic spinal cord injury in adults and adolescents				Recombinant fusion protein.
687	Winfuran (KP 1461)	N*	AIDS/HIV antiretrovirals		Individual					National list remains mixed up: winfuran would have been for treatment of severe uraemic pruritus in patients with end-stage kidney disease on dialysis but the EMA refused a MA on 19/12/13. KP-1461 is an anti HIV drug, the development status of which is currently unclear.
688	Ziconotide	N	Non-opioid analgesics	4.7.1	Individual	Severe, chronic pain				
689	Zidovudine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				
690	Zidovudine with Lamivudine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				
691	Zidovudine with Lamivudine and Abacavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				

A note on the national list states: *Four granulocyte colony stimulating factor (G-CSF) drugs – Filgrastim, Pegfilgrastim, Lenograstim and Lipegfilgrastim – have been removed from the list for 2019/20. However, when these drugs are used for chemotherapy indications they will remain subject to separate reimbursement to which this list adds: where the commissioner is expected to be NHSE*

A further note adds cornea graft tissue to the list of items excluded from national prices **where the commissioner is expected to be NHSE (see Specialised Ophthalmology Service specification)**

<b>Other drugs not listed as Pbr exclusions but NHSE commissioned</b>										
<b>Note:</b> NHSE has been clear that existing GP [=CCG] prescribing of these should NOT be repatriated to NHSE. This section is similar to NHSE's drug list Indications for NHS England drugs list v15 15/04/2020										
No.	Drug Name	Commissioner Category CDF = Cancer drugs fund - check with latest version of NHSE list	PBR Category	BNF category	Group	Indication	Prior Approval Category	Commissioning Policy Type	Commissioning Policy Link	Comments
	3,4 Diaminopyridine	N	Lambert Eaton Myasthenic Syndrome							
	Abemaciclib	N / CDF	Cancer							new to accord with NHSE V15
	Albumin bound paclitaxel	N	Cancer			Treatment of breast cancer patients with documented taxane hypersensitivity				
	Alectinib	N	Cancer			Cancer				
	Arsenic trioxide	N	Cancer			Cancer				

Atezolizumab	N / CDF	Cancer			Cancer			
Autologous Chondrocyte implantation	N				Articular cartilage defect			
Avelumab	N	Cancer						
Axicabtagine	CDF	Cancer						
Azathioprine	N	Immunosuppressants			Transplant immunosuppression only		New patients only until formal repatriation agreed	
Bendamustine	N / CDF	Cancer			Cancer			
Binmetinib	N	Cancer			Cancer			new to accord with NHSE V15
Blinatumomab	N	Cancer			Cancer			
Brentuximab	N	Cancer			Cancer			
Brigatinib	N	Cancer			Cancer			
Cabazitaxel	N	Cancer			Cancer			
Cabozantinib	N / CDF	Cancer			Cancer			
Carfilzomib	N	Cancer			Cancer			
Cemiplimab	CDF	Cancer			Cancer			new to accord with NHSE V15
Ceritinib	N	Cancer			Cancer			
Chemotherapy	N / CDF	Cancer			Cancer			Consult NHSE guidance / spreadsheet for individual drugs
Ciclosporin	N	Immunosuppressants			Transplant immunosuppression only		New patients only until formal repatriation agreed	
Clofarabine	CDF	Cancer			Cancer			
Colestilan	N	Drugs for mineral bone disorders			Adult renal dialysis only			
Dacomitinib	N	Cancer			Cancer			new to accord with NHSE V15
Daratumumab	CDF	Cancer			Cancer			
Dinutuximab	N	Cancer			Cancer			
Docetaxel	N	Cancer			Cancer			
Durvalumab	CDF	Cancer			Cancer			new to accord with NHSE V15
Encorafenib	N	Cancer			Cancer			new to accord with NHSE V15
Eribulin	N	Cancer			Cancer			
Factor X (Cogadex)	N	Blood related products			Hereditary Factor X deficiency			
Gemcitabine (with capecitabine)	N	Cancer			Cancer			
Gemtuzumab	N	Cancer			Cancer			
Ibrutinib	N / CDF	Protein kinase inhibitors			Cancer			
Idelalisib	N	Protein kinase inhibitors			Cancer			
Inotuzumab ozogamicin	N	Cancer			Cancer			
Ipilimumab	N / CDF	Cancer			Cancer			
Lenvatinib	N	Protein kinase inhibitors			Cancer			
Liposomal cytarabine-danorubicin	N	Cancer			Cancer			
Lutetium (177Lu) oxodotreotide	N	Cancer			Cancer			
Mesenchymal stem cells (e.g. Prochymal®)	N				Acute GvHD and other indications (BCSH)			
Midostaurin	N	Cancer			Cancer			
Mycophenolate mofetil	N	Immunosuppressants			Transplant immunosuppression only		New patients only until formal repatriation agreed	



- Recommendations for cancer chemotherapy are to be excluded from 1/4/13. However, non-chemotherapy indications for the following will be CCG commissioned *if* use relates to a non-NHSE service: cladribine, lenalidomide, thalidomide, rilonacet, azacitidine, bevacizumab, bortezomib, cetuximab, protein kinase inhibitors, alemtuzumab.
- Drugs for which NHS England is the Commissioner are not necessarily *routinely* commissioned.
- Many drugs for which NHS England is the Commissioner are only commissioned by NHSE when from Specialist Centres; funding for requests outside of specialist centres would fall to CCGs.

**For information:** [reference A Strategic Framework for Intestinal Failure and Home Parenteral Nutrition Services for Adults in England. National Commissioning Group for Highly Specialised Services April 2008]

Type I – this type of Intestinal Failure is short-term, self limiting and often peri-operative in nature. Type I Intestinal Failure is common and these patients are managed successfully in a multitude of healthcare settings, especially surgical wards, including all units which perform major, particularly abdominal surgery. Some patients on high dependency units (HDU) and intensive care units (ICU) will also fall into this category.

Type II – Type II IF occurs in metabolically unstable patients in hospital and requires prolonged parenteral nutrition over periods of weeks or months. It is often associated with sepsis, and may be associated with renal impairment. These patients often need the facilities of an Intensive Care or High Dependency Unit for some or much of their stay in hospital. This type of IF is rarer and needs to be managed by a multi-professional specialist intestinal failure team. Effective management of Type II IF can reduce the likelihood of the development of Type III Intestinal Failure.

Type III – Type III is a chronic condition requiring long term parenteral feeding. The patient is characteristically metabolically stable but cannot maintain his or her nutrition adequately by absorbing food or nutrients via the intestinal tract.

### Catalogue of Changes made since 11.05 version:

- Abiraterone, carmustine, darafenib, SIRT, vandetinib moved into general chemo line 358
- Updated NICE TA reference for pegloticase
- Pegvisomant changed to NHSE and reason given
- Reason for classification of rilonacept given
- Note about negative NICE TA for ruxolotinib [but NHSE commissioned]
- Order of other non-PbR drugs sorted by therapeutic category and SIRT and MSS added
- **Generally, no attempt is made to provide a prior approval category for NHSE commissioned drugs; consult NHSE documentation for details.**

### January 2014

- Prior approval categories for NHSE commissioned drugs not normally shown, except where stated in V8 / V8.1 documents.
- Spellings of alisporivir, entecavir, peginterferon, reslizumab corrected
- Laquinimod split into 2 commissioners according to indication
- Commissioner for pasireotide changed to NHSE
- Rituximab split over more rows for clarity re NHSE commissioned uses and status in these; **commissioner for refractory idiopathic thrombocytopenia changed to CCG**
- Commissioner for vedolizumab changed to NHS England - and changed back again to CCG
- Collagenase changed to monitored when in line with GMMMG
- Commissioner for co-careldopa changed to NHS England
- Iloprost injection removed: no known formulation; otherwise IFR
- Commissioner for bosentan for digital ulcers changed to NHS England as appears in NHSE's spreadsheet for this

### September 2014

- **Vicriviroc removed; drug never licensed. At 02/16 still in Annex B1 but not in NDO**
- Adalimumab and infliximab for uveitis: NHSE has stated it commissions all uveitis
- Commissioner for anakinra in adult RA changed to CCG and categorised as IFR required
- New drugs for multi drug resistant TB added to NHSE section
- Bone morphogenetic protein now NHSE commissioned
- Acromegaly added to NHSE indication for lanreotide
- Acromegaly and hyperinsulinism added to NHSE indication for octreotide
- Graft versus host disease, myositis and ABO-incompatible kidney transplants added to indications for rituximab for completeness with NHSE spreadsheet
- Sodium oxybate in paediatrics added - NHSE commissioned
- Tocilizumab in large vessel vasculitis added - NHSE commissioned
- Vedolizumab for Crohn's in children added - NHSE commissioned
- Cabozantinib added - NHSE commissioned
- Omalizumab for chronic urticaria added - NHSE commissioned
- Note added to voriconazole that antifungals for ABPA are commissioned by CCGs
- Rows added for adalimumab and infliximab in hidradenitis suppurativa - NHS England

### February 2015

- Co-careldopa commissioner changed to NHSE
- Rilonacept for gout removed
- Teduglutide for Crohn's removed
- Teriparatide for osteoporosis in men commissioner changed to NHSE [ref: PSS No.9]
- Tesamorelin removed
- Vedolizumab in paediatrics commissioner changed to NHSE
- **Vercirnon removed [still in 2016 17 Annex C but not in NDO - Internet suggests no longer being developed]**
- **Category for CCG-commissioned use of bone morphogenetic protein changed to IFR - agreed GMMMG 19/2/15**

### Mar-15

- Row 69 bevacizumab - question mark removed; category is IFR, hyperlink corrected
- Row 61 baricitinib - categorised as IFR
- Row 283 odanacatib - categorised as IFR

- Row 284 ofatumumab - categorised as IFR
- Rows 11, 150, 219, 350: hyperlinks corrected

**Note:** due to further amendments, row numbers above have since changed

#### April / May 2015

- Alteplase may be re-charged: local agreement for hyper acute stroke units
- Anakinra - description amendments to align with NHSE V9 s/sheet also NHSE policy available in Juvenile arthritis so comments re IFR removed.
- Spelling of Kiovig corrected
- Spelling of turoctocog corrected
- Abacavir plus other antivirals moved to abacavir as per NHSE s/sheet. Other antiviral combinations also
- Aztreonam annotated as lysine [=nebulised]
- Bevacizumab for neurofibromatosis added
- Cladribine entries amended to match NHSE descriptions
- Crizotinib added
- Lanreotide and octreotide entries amended to accord with NHSE V9 list.
- Further entries for NHSE-commissioned indications for etanercept, rituximab and tocilizumab
- Botulinum toxin: additional GM monitored indication for use in line with local hyperhidrosis policy

#### February 2016

- Balugrastim removed [not in NDO]
- Faldeprevir removed [not in NDO]
- Deleobuvir removed [not in NDO]
- Laquinimod CCG commissioned indication removed. This has been removed from Annex C but is still on
- Orteronel removed [as indicated on previous version]
- Rilonacept removed [marketing authorisation withdrawn]
- Tabalumab removed [discontinued]
- Mannitol - comment re NHSE commissioning bronchiectasis removed [only applies to children]
- Sildenafil for digital ulcers removed: not PbRe for this indication [only PbRe for PA]
- NHSE states that CCGs are the responsible commissioner for rituximab in non cancerous haematological conditions e.g. ITP and non specialist auto-inflammatory conditions e.g. RA
- NHSE states that eltrombopag and romiplostim are the responsibility of CCGs regardless of the cause of the thrombocytopenia
- NHSE states that it is the responsible commissioner when somatropin analogues (growth hormone) are prescribed in specialist centres for indications falling outside NICE guidance

#### March 2016

- Andexanet removed - not in Annex A NHS National Tariff Payment System 2016/17 and NDO entry updated to suggest in-Tariff
- Sodium benzoate added - new addition to Annex A; no previous entry
- Note about nitisinone removed
- Note that a number of drugs which I have removed because they are no longer being developed remain in the official list, Annex A, published 23rd March 2016

- Iron chelators clarification: only NHS England when used for treatment of haemoglobinopathies; CCG commissioned for MDS (myelodysplastic syndrome). Changed on NHSE s/sheet V8.1
- Tolvaptan clarification: only NHS England when used for treatment of hyponatraemia associated with lung cancer. Changed on NHSE s/sheet V9.1

- Sodium oxybate CORRECTION: catalepsy amended to cataplexy (= licensed indication = what was

#### November 2016

- Row 5: abaloparatide s/c formulation only mentioned on SPS monograph
- Row 7: TA numbers corrected to accord with NHSE V10 s/sheet
- Row 10: actoxumab + bezlotoxumab added as per national list
- Row 28: afamelanotide - entry updated with indication and licensing status
- Row 34: new row added for NICE approved use in BRVO with TA referenced.
- Row 41: albutropin added as per national list
- Row 55: alteplase for MI removed (not in national list)

- Row 70: pseudomonas vaccine inserted as per national list
- Row 73: apremilast. NICE likely to change to positive guidance during the currency of this document.
- Row 74: apremilast. NICE likely to change to positive guidance during the currency of this document.
- Row 81: atacicept added as per national list
- Row 86: avacincaptad pegol added as per national list
- Row 97: begelomab added as per national list
- Row 100: benralizumab added as per national list (NHSE indication)
- Row 101: benralizumab added as per national list (CCG indication)
- Row 107: bimagrumab added as per national list
- Row 110: GM policy for many uses of botulinum will be completed during the currency of this document
- Row 124: brolocizumab added as per national list
- Row 133: ceralifimod added as per national list
- Row 134: cerliponase alfa added as per national list
- Row 137: certolizumab - new row added for new NICE TA
- Row 150: cobitolimod added as per national list
- Row 157: CX601 - updated information including brand name provided
- Rows 162/163: information regarding daclizumab updated.
- Row 181: dexamethasone intravitreal - updated information provided
- Row 191: doravirine added as per national list
- Rows 195 / 196: dupilumab added as per national list. Two indications split.
- Row 201: edratide added as per national list
- Row 213: emricasen added as per national list
- Row 234: eteplirsen added as per national list
- Row 265: halofunginone added as per national list
- Rows 236/237: etrolizumab added as per national list. Two indications split.
- Row 253: fasinumab added as per national list.
- Row 254: fibrin sealants are removed from national list.
- Rows 257/258: filgotinib added as per national list. Two indications split.
- Row 263: fitusiran added as per national list
- Row 272: fostemsavir added as per national list
- Rows 273/274: galcanezumab added as per national list. Two indications split.
- Row 282: gantenerumab added as per national list
- Row 286: glecaprevir added as per national list
- Row 298: halofunginone added as per national list
- Row 306: ibalizumab added as per national list
- Row 344: indications for ixekizumab separated as now launched for plaque psoriasis. Information updated
- Rows 345/346: other indications for ixekizumab separated.
- Row 351: lampalizumab added as per national list
- Row 365: letermovir added as per national list
- Row 366: levodopa + carbidopa added as per national list
- Row 371: lonafamid added as per national list
- Row 374: lusutrombopag added as per national list
- Row 388 (where it would now be): mifepristone in Cushing's removed as no longer in NHSE s/sheet
- Row 391: momlotinib added as per national list
- Row 407: obeticholic acid added as per national list
- Row 426: osilodrostat added as per national list
- Rows 427/428: ozanimod added as per national list. Two indications split. Note different commissioner.
- Row 455: ponesimod added as per national list
- Row 459: pretomanib added as per national list
- Row 456: indication for sarilumab updated
- Row 468: reveglucosidase alfa added as per national list
- Row 498: ropeginterferon alfa-2b added as per national list
- Rows 499/500: roxadustat added as per national list. Two indications split. Note probable different commissioner.

- Row 511: secukinumab in active AS: updated to note NICE TA and category changed to Monitored when in line with NICE
- Row 522: sodium benzoate removed as no longer in national list
- Row 529: solanezumab added as per national list
- Rows 540/541: tafamidis entries updated. Two indications split. Note probable different commissioner.
- Row 543: tanezumab added as per national list
- Row 558: tezacaftor added as per national list
- Rows 570/571: RA separated from other indications for tofacitinib as likely to be available for this indication Q1 2017 (SPS). Plaques psoriasis removed as discontinued for this indication.
- Row 575: tralokinumab added as per national list
- Row 579: trientine added as per national list
- Row 581: uridine triacetate added as per national list
- Row 585: new indication for ustekinumab (Crohn's disease) added
- Rows 587/588: vadadustat added as per national list. Two indications split. Note probable different commissioner.
- Row 590: vancomycin via unique delivery system added as per national list
- Row 605: winfuran added as per national list

#### **January 2017: receipt of updated NHSE list (V11)**

- Row 12 adalimumab - strikethrough as duplicates row 26. Will be removed on next version.
  - Row 39 alafenamide: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 41: albutropin amended to NHSE-commissioned as per V11 s/sheet (SPS thinks CCG)
  - Row 70: pseudomonas vaccine amended to NHSE-commissioned as per V11 s/sheet (as it's for CF)
  - Row 73: apremilast in plaque psoriasis: changed to Monitored when in line with updated positive NICE TA
  - Row 81 atacipet: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 92: note made about NHSE commissioning paediatric indications if a positive NICE TA becomes available for adults.
- 
- Row 97 begelomab: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 100 benralisumab: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 107 bimagrumab: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 109 blisibimod: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 122: brodalumab - note made about NHSE commissioning paediatric indications if a positive NICE TA becomes available for adults.
  - Row 133 ceralifimod: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 134 cerliponase alfa: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 142 chenodeoxycholic acid: primary biliary cirrhosis added to NHSE-commissioned indications
  - Row 163 daclizumab: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 164 damoctocog alfa pegol: asterisk **added**; not present on V11 s/sheet.
  - Row 191 doravirine: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 196 dupilumab amended to NHSE-commissioned in asthma as per V11
  - Row 198 eculizumab: additional NHSE-commissioned indication added: C3 glomerulopathy (post transplant)
  - Row 201 edratide: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 203 efralocotocg: note made re efmorotocog as per V11 (but latter does not appear in national PbRe)
  - Row 208 eltrombopag: note made about NHSE commissioning for children.
  - Row 211 - strikethrough as no longer separately listed by NHSE - to be removed on next version.
  - Row 213 emricasan: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 214 emtricitabine combination product with tenofovir alafenamide to be added to accord with V11.
  - Row 219 epoprostenol: note added to acord with NHSE list; same text as per iloprost in previous version.
  - Row 234 etreplirsen: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 236 etrolizumab: note made about NHSE commissioning paediatric indications if a positive NICE TA becomes available for adults
  - Row 244 Holoclar: asterisk removed; NHSE confirmed as commissioner on V11. Some explanatory text removed.

- Row 249 Factor VIII Fc fusion protein: asterisk **added**; not present on V11 s/sheet.
  - Row 257 filgotinib - note made about NHSE commissioning paediatric indications if a positive NICE TA becomes available for adults.
  - Row 263 fitusiren: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 272 fostemsavir: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 306 ibralizumab: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 307 icabitan: prophylactic treatment added to accord with V11
  - Row 353 lanreotide: note made about NHSE responsibility when prescribed in specialist centres
  - Row 360 lebrikuzumab amended to NHSE-commissioned in asthma as per V11
  - Row 361 ledipasvir: asterisk **added**; not present on V11 s/sheet.
  - Row 365 letermovir: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 371 lonafarnib: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 380 mavrilimumab: note made about NHSE commissioning paediatric indications if a positive NICE TA becomes available for adults
  - Row 391 momelotinib: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 407 obeticholic acid: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 414 octreotide: note made about NHSE responsibility when prescribed in specialist centres
  - Rows 418 / 419 odanacatib: updated information regarding discontinued development
  - Row 426 osilodrostat: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 427 ozanimod: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 455 ponesimod: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 457 porcine factor: asterisk **added**; not present on V11 s/sheet.
  - Row 459 pretomanib: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 468 reveglucosidase alfa: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 497 romiplostim: note made about NHSE commissioning for children.
  - Row 498 ropeginterferon alfa-2b: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 500 roxadustal: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 506 sarilumab: note made about NHSE commissioning paediatric indications if a positive NICE TA becomes available for adults
  - Row 517 siltuximab: asterisk **added**; not present on V11 s/sheet.
  - Row 520 sirukumab: note made about NHSE commissioning paediatric indications if a positive NICE TA becomes available for adults
  - Row 536 sucroferric oxyhydroxide: V11 has this in the wrong place. It *is* PbRe.
  - Row 552: Further entries of combination products required to match NHSE s/ sheet but all products containing tenofovir are commissioned by NHSE
  - Row 558 tezacaftor: Commissioner changed to NHSE as on V11 (despite National list saying 'non-CF'.)
  - Row 567 tocilizumab: NHSE indications updated
  - Row 575 tralokinumab: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 579 trientine: asterisk removed; NHSE confirmed as commissioner on V11
  - Row 588 vadadustat: asterisk removed; NHSE confirmed as commissioner on V11. Now in SPS
  - Row 593 vedolizumab: NHSE entry modified to "inflammatory bowel disease" from "Crohn's"
  - Row 605 winfuran / KP-1461: additional information provided.
- NHSE-commissioned non-PbR:** entries adjusted to accord with V11 including mention of CDF.
- NHSE-commissioned non-PbR cinacalcet: this row removed. Note amended to be clear that this drug is not otherwise PbRe (i.e. in Tariff).
- NHSE-commissioned non-PbR dabrafenib :asterisk added; not present on V11 s/sheet but present on previous versions. Licensed drug.
- NHSE-commissioned non-PbR osimertinib: new drug added as per V11
- NHSE-commissioned non-PbR pegaspargase: new drug added as per V11
- NHSE-commissioned non-PbR ponatinib :asterisk added; not present on V11 s/sheet but present on previous versions. Licensed drug.
- NHSE-commissioned non-PbR sirolimus for lymphangioleiomyomatosis (LAM): this row removed (was removed from V10).
- NHSE-commissioned non-PbR talimogene laherparepvec: new drug added as per V11

NHSE-commissioned non-PbR trastuzumab: new drug added as per V11

NHSE-commissioned non-PbR trifluridine + tipiracil: new drug added as per V11

### January 2018

- Row 20: reference updated to latest GMMMG biologics in psoriasis pathway
- Row 92: reference updated to latest GMMMG biologics in RA pathway; NICE TA referenced
- Row 125: description amended to better match NHSE V12 list
- Rows 138,139: reference updated to latest GMMMG biologics in AS / PsA pathway
- Row 139: NICE TA referenced
- Row 153: NICE TA referenced
- Row 15: New drug name for this product: darvadstrocel
- Row 234: reference updated to latest GMMMG biologics in psoriasis pathway
- Rows 229,230: reference updated to latest GMMMG biologics in AS / PsA pathway
- Rows 231,232: reference updated to latest GMMMG biologics in RA pathway
- Rows 291,292: reference updated to latest GMMMG biologics in AS / PsA pathway
- Rows 293,294: reference updated to latest GMMMG biologics in RA pathway
- Row 327: reference updated to latest GMMMG biologics in AS / PsA pathway
- Rows 328,329: reference updated to latest GMMMG biologics in psoriasis pathway
- Row 330: reference updated to latest GMMMG biologics in AS / PsA pathway
- Row 344: reference updated to latest GMMMG biologics in psoriasis pathway
- Row 345: likely time to market for this indication updated
- Row 346: likely time to market for this indication updated
- Row 506: reference updated to latest GMMMG biologics in RA pathway; NICE TA referenced
- Row 510: reference updated to latest GMMMG biologics in AS / PsA pathway; NICE TA referenced
- Row 529: new row inserted to accord with NHSE V12 list
- Row 571: reference updated to latest GMMMG biologics in RA pathway; NICE TA referenced
- Row 584: reference updated to latest GMMMG biologics in psoriasis pathway
- Row 586: reference updated to latest GMMMG biologics in IBD pathway; NICE TA referenced
- Row 594: description amended to better match NHSE V12 list

### February, March, April 2018

- Row 6: updated advice for children transitioning to adult services
- Former row 12 removed due to duplication with row 25
- Row 12: spelling of \*hidradenitis\* suppurativa corrected
  - Row 13: updated advice for children transitioning to adult services
  - Row 25: NICE TAs updated as per NHSE V13 s/s
  - Row 35: new row inserted for new positive NICE TA.
- Following row numbers remain the same as previous version.*
- Row 118: amended to reference new GM commissioning policy
  - Row 163: strikethrough - drug withdrawn. Left for reference for time being.
  - Row 181: category changed to monitored as NICE TA now available
  - Row 185: reference to review removed as agreed at Review group
  - Row 188: category changed to monitored as NICE TA now available
  - Row 195: GMMMG recommendation now in production.
  - Row 223: reference to review removed as agreed at Review group
  - Row 225: NICE TAs updated as per NHSE V13 s/s
  - Row 226: updated advice for children transitioning to adult services
  - Row 290: updated advice for children transitioning to adult services
  - Row 291: new reference to NICE TA497
  - Row 318: updated advice for children transitioning to adult services
  - Row 355: new statement regarding commissioner in adult congenital hyperinsulinism
  - Row 362: POEMS added to NHSE-funded indications; will be separate line on next version.
  - Row 416: new statement regarding commissioner in adult congenital hyperinsulinism
  - Row 417: new GMMMG recommendation for use in gastrointestinal conditions for which category changed to monitored; hyperlink to recommendation inserted

- Row 492: new GMMMG recommendation for use in refractory ITP and AIHA included; category changed to monitored; hyperlink to recommendation inserted
- Rows 541/542: commissioner clarified as NHSE
- Row 566: updated advice for children transitioning to adult services
- Rows 573-575: brand names added to match indications for clarity
- Rows 574: category clarified to be Individual Funding as agreed at review group
- Rows 619 onwards: new drugs added 04/18 to accord with NHSE V13 list

#### April 2019

All named drugs in the category 'Intravenous/subcutaneous human normal immunoglobulins' removed from the list and replaced with the following two descriptions – 'Intravenous human normal immunoglobulins' and 'Subcutaneous human normal immunoglobulins'. Consequently, almost all row numbers changed from previous version and no longer referenced here.

Group and individual categories changed for some drugs.

All removals below are because the drug is no longer in the national list.

Links to GMMMG biologics pathways updated

Amendments made to NHSE list at foot of the s/sheet to accord with NHSE version V14 issued 04/04/19

- Abaloparatide: development status updated
- Abatacept in psoriatic arthritis - new row added for negative NICE TA
- Actoxumab + Bezlotoxumab - removed
- Abicipar - new drug added with indication and likely commissioner
- Afamelanotide - question about commissioner
- Albutrepenonacog alfa removed
- Alicaforsen - new drug added with likely indication and commissioner
- Alpha-1 antitrypsin commissioner changed to CCG in emphysema
- Amikacin inhalation indication changed as development for ventilator assisted pneumonia has ceased
- Anabasum - new drug added with likely indication and commissioner
- Anifrolumab - new drug added with likely indication and commissioner
- Amiselimod - new drug added with likely indication and commissioner
- Andexanet alfa - new drug added with likely indication and commissioner
- Apremilast now with positive NICE TA in PsA and category changed to monitored
- Arimoclomol - new drug added with likely indication and commissioner
- Autologous eye serum drops - new drug added with likely indication and commissioner
- Avoralast - removed
- Avacopan - new drug added with likely indication and commissioner
- Bardoxolone methyl - new drug added with likely indication and commissioner
- Beractant - removed
- Beperminogene perplasmid - new drug added with likely indication and commissioner
- Bezlotoxumab expected to be CCG commissioned
- Brodalumab NICE TA added and category changed to monitored
- Burosumab new drug added with likely indication and commissioner
- Cabotegravirb new drug added with likely indication and commissioner
- Calcifediol new drug added with likely indication and commissioner
- Cannabidiol new drug added with likely commissioner
- Caplacizumab new drug added with likely indication and commissioner
- Catridecacog removed
- Cengermin new drug added with likely indication and commissioner
- Certolizumab pegol for psoriasis updated with positive NICE TA
- Cinacalcet new drug added with likely commissioner
- Clazakizumab row split to provide two separate indications with relevant commissioner
- Cobitolimod new drug added with likely indication and commissioner
- Crizanlizumab new drug added with likely indication and commissioner
- Darvadstrocel (CX601) category changed to exceptional case after negative NICE TA
- Darbepoetin alfa new drug added with likely commissioner

- Dexamethasone intra-erythrocyte new drug added with likely indication and commissioner
- Dichlorphenamide new drug added with likely indication and commissioner
- Diroximel fumarate new drug added with likely indication and commissioner
- Domagrozumab new drug added with likely indication and commissioner
- Dupilumab category changed to monitored and NICE TA referenced
- Ecallanatide entry updated - drug is not discontinued
- Edasalonexent new drug added with likely indication and commissioner
- Emapalumab new drug added with likely indication and commissioner
- Emtricitabine combination removed - NHSE list now contains many so grouped
- Emicizumab new drug added with likely indication and commissioner
- Epoetins new drug added with likely commissioner
- Eptinezumab new drug added with likely indication and commissioner
- Erenumab new drug added with likely commissioner
- Etelcalcetide new drug added with likely commissioner
- Everolimus (Votubia) indications separated
- Fidaxomicin new drug added with likely commissioner
- Filgotinib new indication (UC) added
- Filgrastim removed
- Fremanezumab new drug added with likely indication and commissioner
- Gantenerumab entry updated (still under development)
- Gevokizumab entry updated (developmental status now unknown)
- Givosiran new drug added with likely indication and commissioner
- Grazoprevir additional row added to match national list
- Human alpha1-proteinase inhibitor new drug added with likely indication and commissioner
- Human arginate now called haem arginate
- Hydroxypropyl betadex new drug added with likely indication and commissioner
- Idebenone for Friedrich's ataxia removed as not in SPS nor on NHSE V14
- IL6 receptor MAb (SA237, satralizumab) new drug added with likely indication and commissioner
- Imetelstat new drug added with likely indication and commissioner
- Inebilizumab new drug added with likely indication and commissioner
- Inotersen new drug added with likely indication and commissioner
- Interferon alpha-n3 indication added and commissioner changed to CCG for this indication
- Intravenous human normal immunoglobulins new drug added with indication and commissioner
- Lanadelumab new drug added with likely indication and commissioner
- Lanthanum new drug added with likely indication and commissioner
- Lebrikizumab potential indication and thus commissioner changed
- Lenograstim removed
- Leronlimab new drug added with likely indication and commissioner
- Levoketoconazole new drug added with likely indication and commissioner
- Lipofilgrastim removed
- Lustrombopag commissioner set to CCG (from ?NHSE)
- Luspatercept new drug added with likely indication and commissioner
- Maralixibat new drug added with likely indication and commissioner
- Maraviroc additional row added to match NHSE V14
- Maribavir new drug added with likely indication and commissioner
- Mexilitine new drug added with indication and likely commissioner
- Momelotinib new drug added with likely indication and commissioner
- Motavizumab removed
- Nexobrid new drug added with likely indication and commissioner
- Nonacog alpha removed
- Nonacog beta pegol removed
- Nusinersen new drug added with likely indication and commissioner
- Odanacatib removed
- Paracalcitol new drug added with likely indication and commissioner

- Patisiran new drug added with likely indication and commissioner
- Pegaptanib removed
- Pegbelfermin new drug added with likely indication and commissioner
- Pegfilgrastim removed
- Peginterferon Lambda-1a removed
- Pegloticase removed
- Pegpleranib removed
- Pegunigalsidase alfa new drug added with likely indication and commissioner
- Pegvaliase new drug added with likely indication and commissioner
- Pibrentasvir new drug added with likely indication and commissioner
- Pitolisant new drug added with likely indication and commissioner
- Poloxamer 188 new drug added with likely indication and commissioner
- Practant alfa removed
- Porcine factor removed
- Pretomanid new drug added with likely indication and commissioner
- Ravulizumab new drug added with likely indication and commissioner
- Raxibacumab new drug added with likely indication and commissioner
- Refenalin new drug added with likely indication and commissioner
- Reloxaliase new drug added with likely indication and commissioner
- Reltecimod new drug added with likely indication and commissioner
- Reparixin new drug added with likely indication and commissioner
- Ribavirin removed
- Riluzole removed
- Rimeporide new drug added with likely indication and commissioner
- Rintatolimod new drug added with likely indication and commissioner
- Risankizumab new drug added with likely indication and commissioner
- Rivipansel sodium new drug added with likely indication and commissioner
- Rituximab: NHSE is responsible commissioner for nephrotic syndrome in adults and children.
- Rituximab: additional NHSE indications added to match NHSE V14
- Romosozumab new drug added with likely indication and commissioner
- Rurioctocog alfa pegol new drug added with likely indication and commissioner
- Ruzasvir new drug added with likely indication and commissioner
- Sacrosidase new drug added with likely indication and commissioner
- Satralizumab new drug added with likely indication and commissioner
- Seralexin removed
- Setrobuvir removed
- Sevelamer new drug added with likely indication and commissioner
- Sialic acid removed
- Sildenafil (PAH) removed
- Siponimod new drug added with likely indication and commissioner
- Sirolimus new drug added with likely indication and commissioner
- Sirolimus (intravitreal) new drug added with likely indication and commissioner
- Sirukumab updated by removing note 'not on NICE's agenda'
- Sodium benzoate removed
- Solriamfetol new drug added with likely indication and commissioner
- Somapacitan new drug added with likely indication and commissioner
- Somatrogen new drug added with likely indication and commissioner
- Subcutaneous human normal immunoglobulins new drug added with likely indication and commissioner
- Susoctocog alfa removed
- Tabalumab new drug added with likely indication and commissioner
- Tadalafil (PAH) removed
- Tanezumab new drug added with likely indication and commissioner
- Thrombin removed
- Tildrakizumab category changed to monitored with link to NICE TA added

- Tofacitinib category changed to monitored for ulcerative colitis with link to NICE TA added; extra row added for any other indication outside of NICE TAs where category is IFR
- Tralokinumab additional row added for new potential indication of atopic dermatitis where commissioner would be CCG
- Treprostinil diethanolamine removed
- Treprostinil sodium removed
- Triheptanoin new drug added with likely indication and commissioner
- Turoctocog alfa removed
- Upadacitinib new drug added with likely indication and commissioner
- Valbenazine new drug added with likely indication and commissioner
- Vatiquinone new drug added with likely indication and commissioner
- Velmanase alfa new drug added with likely indication and commissioner
- Vestronidase alfa new drug added with likely indication and commissioner
- Velmanase alfa new drug added with likely indication and commissioner
- Voclosporin new drug added with likely indication and commissioner
- Volanesorsen new drug added with likely indication and commissioner
- Von Willebrand factor changed from 'recombinant' to 'analogue' to match national list
- Vonicog alfa new drug added with likely indication and commissioner
- Voretigene neparvovec new drug added with likely indication and commissioner
- Voxelotor new drug added with likely indication and commissioner
- VX-210 (Cethrin) new drug added with likely indication and commissioner

#### October 2019

- Bezlotoxumab entry updated as per NICE TA. As the manufacturer didn't make a submission and NICE is unable to produce a TA, this drug is not routinely commissioned and an exceptional case would have to be
- Dupilumab entry updated to account for NHSE SS2082 which states CCGs fund treatment of adolescents 16-18 years old being treated in adult centres
- Diboterminalfa changed to monitored approval when in line with GMMMG recommendation
- Fluocinolone implant. Additional row inserted for new NICE TA

#### January 2020

Where there is a negative NICE TA, category has been re-defined as "Not routinely commissioned"

- Botulinum toxin. GMMMG recommendation hyperlink updated.
- Clazakizumab now in SPS but only for renal transplant chronic active antibody-mediated rejection. Therefore mention of use in arthritides will be removed for 20/21 FY.
- Fluocinolone implant. Additional row inserted for new NICE TA 613.
- Liothyronine category changed to GMMMG recommendation

#### January 2020 Version 3.1

- Botulinum toxin. GMMMG recommendation hyperlink updated to very latest version as placed on GMMMG website January 2020.

#### June 2020

Hyperlinks to GM and NICE documents updated where appropriate

For new drugs or those where a commissioning position is not available, category changed to "not routinely commissioned", meaning *In the absence of a submission from local clinicians this treatment is not routinely commissioned. The publication of a NICE TA will supersede this interim position*

- Actoxumab added.
- Adalimumab for psoriasis in children added - NHSE commissioned
- Andexanet alfa - spelling corrected
- Asunaprevir + Daclatasvir combination, also these two with beclabuvir removed as not shown on national list nor NHSE V15
- Ataluren for cystic fibrosis removed - no longer shown in SPS
- Benralizumab. New row inserted for nasal polyposis indication

- Boceprivir. Removed from NHSE list and proposed for removal from national list. Will be removed next time if removed from national list.
- Brodalumab. Row for psoriatic arthritis removed as SPS says no longer being developed for this indication.
- Calcifediol comments amended.
- Caplacizumab. Commissioner changed to NHSE as now added to V15
- Collagenase. Product withdrawn but kept on list to accord with national list
- Daclatasvir. Removed from NHSE list and proposed for removal from national list. Will be removed next time if removed from national list.
- Eculizumab. Four rows to match NHSE s/sheet
- Eltrombopag. Additional row to match NHSE list which notes NHSE commissions in children
- Evinacumab. New drug with commissioner added
- Fedratinib. New drug with commissioner added
- Fenfluramine. New drug with commissioner added
- Filgotinib indications amended and all potential indications condensed into one row. May be re-split on receipt of NICE guidance for a particular indication.
- Fluocinolone implant. Indications corrected
- Gosuranemab. New drug with commissioner added.
- Granulocyte-macrophage colony-stimulating factor (Leukine - Import). Entry removed - not in national list but remains on V15
- Idarucizumab category changed to monitored as per instruction from HCDOG
- Imlifidase. New drug with commissioner added.
- Infliximab. List of NHSE indications made alphabetical although these are not alphabetical on V15
- Lusutrombopag category changed to monitored and new NICE TA link provided
- Mavrilimumab commissioner changed to NHSE in view of new information about likely use
- Metreleptin entries amended to match both NHSE V15 and SPS
- Ofatumumab entries amended
- Olipudase alfa. New drug with commissioner added
- Olokizumab. New drug with commissioner added
- Palvarotene. New drug with commissioner added
- Piclenodorson. New drug with commissioner added
- Platelet lysate-based therapy . New drug with commissioner added
- Risdiplam. New drug with commissioner added
- Romiplostim. Commissioners separated to accord with entry in NHSE V15
- Sestrizumab. New drug with commissioner added
- Sirukumab. Reference to use in giant cell arteritis removed
- Siltuximab. Commissioner and commissioner updated
- Simeprvir. Removed from NHSE list and proposed for removal from national list. Will be removed next time if removed from national list. Combination product also removed from this list.
- Sirolimus intravitreal. Commissioner changed
- Sofosbuvir / daclatasvir + ribavirin. Row removed as no longer on NHSE list
- Somapacitan. Indications and thus commissioners split
- Somatropin. Note to clarify commissioner
- Satimlimab. New drug with commissioner added
- Tabalumab. V15 confirms NHSE as commissioner
- Telaprevir. Removed from NHSE list and proposed for removal from national list. Will be removed next time if removed from national list.
- Tenofovir entries amended to match NHSE list
- Teprasiran. New drug with commissioner added
- Teprotumumab. New drug with commissioner added
- Tezepelumab. New drug with commissioner added
- Thrombin. Drug removed as not on national nor NHSE lists
- Thrombomodulin. Commissioner changed as now on NHSE V15 although indication is questionable
- Tocilizumab. IV distinction removed, new indication added to match V15
- Tofacitinib paediatric reference removed as not on NHSE V14 or V15 lists

- Treprostinil entries removed as not on national not NHSE V15 lists
- Ustekinumab. New NICE TA for ulcerative colitis June 20 with reference added
- Vancomycin in unique delivery system. Commissioner may be CCG as for MRSA infection.
- Voclosporin. New indication and commissioner added
- Vonicog alfa. Commissioner confirmed as NHSE on V15
- Voretigene neparvovec . Leber('s) indication removed as not on NHSE V15
- Winfuran (KP 1461). Proposed for removal from national list. Will be removed next time if removed from national list.